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1. INTRODUCTION 
The immune system is divided into the innate immune system, which provides 
the first non-specific response, and the adaptive immune system, which elicits a 
highly specific response that involves immunological memory. Monocytes, 
macrophages and dendritic cells (DCs) are essential components of the innate 
immune system that recognise and mediate the clearance of harmful agents and 
have crucial roles in maintaining immune homeostasis in organisms. DCs are 
the main antigen-presenting cells and provide the link between the immune 
responses. 
In normal conditions, DCs are generated from common DC precursors 
(CDPs), but in the case of infection, DCs are rapidly generated in large numbers 
during the monocyte stage. Monocyte-derived DCs are under going extensive 
study and are currently the most promising cell type to be used in immuno-
therapy for cancer and various autoimmune diseases. However, many challen-
ges remain in the introduction of these therapies to the clinic (Lesterhuis et al., 
2008; Eubel and Enk, 2009; Van Brussel et al., 2013). 
As DCs are rare in human blood, in vitro generated monocyte-derived 
dendritic cells are used as substitutes for their study as they are easy to generate 
in large numbers. In our model, we used monocyte-derived macrophages and 
DCs generated in the presence of granulocyte macrophage colony-stimulating 
factor (GM-CSF) alone or in combination with interleukin 4 (IL-4).  
Recent evidence shows the importance of epigenetics in the regulation of 
gene expression, affecting processes such as cell cycle regulation, development, 
differentiation, ageing, X chromosome inactivation and the response to environ-
mental and biological modifications. Epigenetic mechanisms include: histone 
modifications, which mark active or inactive genes; microRNAs, which mainly 
negatively regulate gene expression by inhibiting translation or degrading of 
mRNA; and DNA methylation, a cytosine methylation that occurs in context of 
CpG dinucleotides and represents gene silencing (Tammen et al., 2012). Epi-
genetic patterns change gradually in response to cellular and environmental 
stimuli. Aberrant epigenetic patterns are described in several different biological 
processes, including cancers, various diseases and ageing (Portela and Esteller, 
2010). 
This thesis focuses on the study of different epigenetic aspects affecting 
monocytes, monocyte-derived macrophages and DCs, including correlations of 
gene expression with histone modifications in promoters and the expression of 
microRNAs in these cells. In addition, the DNA methylation patterns of mono-
cytes during ageing were studied. 
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2. REVIEW OF LITERATURE 
2.1. The mononuclear phagocyte system 
The immune system encompasses several different cells and molecules that 
protect the host organism by activating cascades of defence reactions that ensure 
the recognition and elimination of potentially harmful agents. The latter include 
microbe components, macromolecules (proteins and polysaccharides) and small 
chemicals that are recognised as foreign, regardless of their physiological or 
pathological origin. The immune response consists of innate and adaptive 
immunity that together provide defence against pathogens. Innate immune cells 
(monocytes, macrophages, dendritic cells, natural killer lymphocytes) provide a 
rapid but less specific response to pathogens when compared to adaptive immune 
cells (B and T lymphocytes). Adaptive immunity provides a highly antigen-
specific response and also immunological memory (Abbas and Janeway, 2000).  
 
 
 
Figure 1. Monocyte, macrophage and dendritic cell (DC) differentiation lineages. 
Hematopoietic stem cells (HSC) produce myeloid (MP) and lymphoid progenitors (LP). 
MPs differentiate into monocyte, macrophage and DC progenitors (MDP), which 
further differentiate into monocytes or move into the population of macrophage and 
common DC progenitors (CDP). Monocytes leave the bone marrow and under normal 
conditions they differentiate into tissue-resident macrophages. During inflammation, 
monocytes differentiate into monocytes-derived DCs, for example tumour necrosis 
factor and inducible nitric oxide synthase DCs (TipDCs), and to classically (M1 MF) 
and alternatively activated macrophages (M2 MF). In some conditions, they differen-
tiate into the microglia and Langerhans cells (LC). In the other branch of differentiation, 
CDPs differentiate into pre-classical DCs (pre-cDCs) and plasmacytoid dendritic cells 
(pDC) that enter lymphoid tissues through the blood, where pre-cDCs differentiate into 
classical DCs (cDC). Modified from (Geissmann et al., 2010; Lawrence and Natoli, 
2011). 
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DCs act as connective bridges between innate and adaptive immune systems. 
They recognise pathogens by pattern-recognition receptors and mediate clea-
rance through activating T cells and potentiating antibody secretion (Steinman, 
2011). DCs as well as monocytes and macrophages have a crucial role in 
maintaining homeostasis in organisms. DCs, monocytes and macrophages 
originate from the same type of hematopoietic stem cell (HSC) in bone marrow 
and are differentiated in the mononuclear phagocyte system (MPS) (Figure 1). 
Commitment to a mononuclear phagocyte lineage is determined at the macro-
phage and DC progenitor (MDP) stage. By this stage, erythroid, megakaryo-
cyte, lymphoid and granulocyte fates have been excluded. MDPs differentiate 
into monocytes and CDPs (Fogg et al., 2006; Auffray et al., 2009). CDPs are 
proliferative cells that differentiate into plasmacytoid dendritic cells (pDC) and 
pre-classical dendritic cells (pre-cDC), but they have lost the ability to diffe-
rentiate into monocytes (Naik et al., 2007; Onai et al., 2007; Liu et al., 2009). 
Pre-cDCs migrate via the blood into lymphoid organs and peripheral tissues, 
where they acquire a cDC phenotype. In contrast, pDCs develop fully in the 
bone marrow before they enter the bloodstream and migrate into multiple tis-
sues (Shortman and Naik, 2007). MDPs also have the potential to differentiate 
into a monocyte lineage that can further differentiate into macrophages or DCs.  
 
 
2.1.1. Monocytes 
Monocytes are circulating white blood cells that originate from myeloid pro-
genitors in bone marrow (Fogg et al., 2006) and can further differentiate into 
tissue macrophages and DCs (Auffray et al., 2009) (Figure 1). They have 
several roles, including phagocytosis, cytokine production, “patrolling” the 
vascular endothelium, antigen processing and antigen presentation. Monocytes 
also differentiate into monocyte-derived DCs and macrophages, which are 
rapidly recruited to sites of infection, where they can phagocytose pathogens 
and initiate tissue repair (Gordon and Taylor, 2005; Auffray et al., 2009).  
Monocytes in peripheral blood are a heterogeneous population that can be 
divided into three subpopulations by their CD14 and CD16 surface molecules: 
classical CD14++CD16- monocytes that express high levels of CD14, but not 
CD16; intermediate CD14++CD16+ monocytes that express high levels of CD14 
and a lower level of CD16; and non-classical CD14+CD16++ monocytes that 
express very high levels of CD16 and a lower level of CD14 on their surface 
(Ziegler-Heitbrock et al., 2010). All monocyte cell types are developmentally 
linked and differentiate from classical monocytes through intermediates to non-
classical subpopulations. Classical monocytes either leave the circulation and 
differentiate into DCs and macrophages or further differentiate into intermediate 
monocytes that can also either leave the circulation or become non-classical 
monocytes. During an infection, there is an increase of classical, then inter-
mediate and finally non-classical monocytes (Weiner et al., 1994). 
Classical CD14++CD16- monocytes are the most prevalent subset of mono-
cytes in human blood (approximately 90%). They express CCR2 (Geissmann et 
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al., 2003) and are rapidly recruited to sites of infection and inflammation 
(Serbina et al., 2008). Chemokine receptor CCR2 has a crucial role in the 
trafficking of monocytes to the site of inflammation; monocyte trafficking is 
clearly reduced when CCR2 is deficient (Kurihara et al., 1997; Kuziel et al., 
1997). Classical monocytes have high phagocytic activity but low cytokine 
producing properties (Ziegler-Heitbrock, 2000). The CD16+ monocyte popu-
lation, consisting of CD14++CD16+ intermediate and CD14+CD16++ non-
classical monocytes (Ziegler-Heitbrock et al., 2010), represent approximately 
10% of the total monocyte population. CD14+CD16++ non-classical monocytes 
adhere to and migrate along the endothelial cell surface of blood vessels in a 
“patrolling” process and produce proinflammatory cytokines, such as tumour 
necrosis factor α (TNF-α), interleukin-1β (IL-1β) and CCL3, in response to 
viruses and nucleic acids (Cros et al., 2010). The third subpopulation, 
CD14++CD16+ intermediate monocytes, are found at low frequency and have 
distinct features. The number of these cells increases after cytokine treatment 
and during inflammation (Skrzeczynska-Moncznik et al., 2008; Moniuszko et 
al., 2009). This subset of monocytes also express pro-angiogenic markers and 
have pro-angiogenic properties (Zawada et al., 2011). 
 
 
2.1.2. Macrophages 
Tissue macrophages have an important role in regulation of tissue homeostasis 
through the elimination of senescent cells and the remodelling and repair of 
tissues after inflammation. In normal conditions, macrophages have anti-inflam-
matory properties, as they maintain tissue homeostasis by removing toxic mole-
cules and dead or dying cells (Mosser and Edwards, 2008; Biswas and Manto-
vani, 2010; Rivollier et al., 2012). Macrophages express pattern-recognition 
receptors that identify pathogen- or damage-associated patterns expressed by 
pathogens or by host cells during cellular senescence (Gordon and Taylor, 
2005). Under inflammatory conditions, macrophages become activated and 
produce several mediators that recruit neutrophils and promote the inflam-
mation process (Denning et al., 2007; Mosser and Edwards, 2008; Rivollier et 
al., 2012). There are several subpopulations of macrophages that have been 
described based on their location and function: osteoclasts in bone, alveolar 
macrophages in lungs, histiocytes in interstitial connective tissue, Kupffer cells 
in liver, secondary lymphoid organ macrophages in lymph nodes and spleen and 
multiple types of macrophages in the gut and central nervous system (Gordon 
and Taylor, 2005). Although the names and the phenotypes vary, they all have 
macrophage properties and have similar functional capabilities when activated. 
Macrophages are also divided into functional subpopulations based on their 
specific activities (Biswas and Mantovani, 2010) (Figure 1). Classically acti-
vated macrophages (M1 macrophages) are activated by Toll-like receptor 
ligands and interferon-γ and mediate defence against bacteria, protozoa and 
viruses and antitumour immunity. M1 macrophages are pro-inflammatory and 
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antimicrobial (Sindrilaru et al., 2011). They produce large amount of TNF, IL-
12 and IL-23 and are important drivers for T helper 1 (Th1) and Th17 cell 
responses (Krausgruber et al., 2011). Classically activated macrophages play an 
important role in chronic inflammation and autoimmune diseases, including 
rheumatoid arthritis, atherosclerosis, pulmonary fibrosis and Crohn’s disease 
(Smith et al., 2009; Wilson et al., 2010; Woollard and Geissmann, 2010).  
Alternatively activated macrophages (M2 macrophages) are activated by 
signals from the Th2 type cytokines IL-4 and IL-13 (Gordon, 2003). M2 
macrophages promote the encapsulation of parasites (Noel et al., 2004), tissue 
repair and remodelling (Wynn, 2004). In wound healing, M2 macrophages are 
rapidly recruited to the site of tissue injury, where they secrete a wide variety of 
cytokines, chemokines, matrix metalloproteinases and their inhibitors, which in 
turn regulate the deposition of extracellular matrix components (Wynn, 2004). 
M2 macrophages antagonise the functions of M1 macrophages, thereby starting 
wound healing and restoring the tissue homeostasis process (Sindrilaru et al., 
2011). In addition to M1 and M2 macrophages, regulatory macrophages, 
tumour-associated macrophages and the monocytic subset of myeloid-derived 
suppressor cells have been described (Mosser and Edwards, 2008).  
 
 
2.1.3. Dendritic cells 
DCs are a migratory group of leukocytes that are specialised for the uptake, 
transport, processing and presentation of antigens to B and T lymphocytes 
(Steinman, 1991; Matzinger, 1994; Hart, 1997). In normal situations, DCs are at 
an immature stage of development. An encounter with a microbe or with tissue 
damage initiates migration of the DC to the lymph nodes (Randolph et al., 
2005). Encountered antigenic samples are processed and presented on the cell 
surface by the major histocompatibility complex (MHC) II molecules of mature 
and activated DCs (Guermonprez et al., 2002; Trombetta and Mellman, 2005). 
DCs can be activated by a series of microbial products, such as bacterial DNA, 
viral RNA, lipopolysaccharides (LPS) and products from dying cells (Hartmann 
et al., 1999; Verdijk et al., 1999; Singh-Jasuja et al., 2000). Antigen-presenting 
DCs can efficiently trigger an immune response by activating T lymphocytes 
carrying the specific receptor (Cyster, 1999). The main function of DCs is to 
initiate antigen-specific adaptive immune responses to foreign antigens (Stein-
man and Banchereau, 2007) and to maintain tolerance to self antigens (Stein-
man et al., 2003). 
DCs are categorised into two main cell populations consisting of classical 
dendritic cells (cDC) and plasmacytoid dendritic cells (pDC) (Heath and 
Carbone, 2009). cDCs, which mainly populate lymphoid and non-lymphoid or-
gans, are specialised to process and present antigens (Villadangos and Schnor-
rer, 2007; Segura and Villadangos, 2009; Joffre et al., 2012). cDCs are mobile 
cells that can move from tissues to the secondary lymphoid organs, which 
contain B and T cells, and initiate the adaptive immune response (Banchereau 
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and Steinman, 1998; Randolph et al., 2005). In an immature state, cDCs have 
high phagocytic activity but low expression of MHC-I and -II proteins. After 
activation, cDCs transport MHC complexes to the cell surface and acquire co-
stimulatory molecules and the capacity to produce cytokines (Banchereau and 
Steinman, 1998; Mellman and Steinman, 2001).  
pDCs are rare (0.3–0.5% of human peripheral blood) cells that also originate 
from bone marrow progenitors (Naik et al., 2007) and reside in steady state in 
the lymphoid organs. They develop fully in bone marrow and enter lymph 
nodes by circulation in the blood (Randolph et al., 2008; Sozzani et al., 2010). 
In steady state, they have an impaired capacity to populate non-lymphoid organs 
and their phagocytosis, processing and presentation of extracellular antigens is 
limited (Villadangos and Young, 2008). Upon activation, they produce abun-
dant quantities of type I interferons (Liu, 2005) and gain antigen presentation 
properties (Colonna et al., 2004). Together, these signals lead to the recruitment 
and activation of almost all immune cell types (Jego et al., 2003; Krug et al., 
2004).  
In the case of infection, numerous monocytes are recruited to the site of 
infection or inflammation (Shi et al., 2011) and generate a large population of 
monocyte-derived or inflammatory DCs that can outnumber other tissue-
resident DCs (Iijima et al., 2011). Autoimmune diseases are usually accom-
panied by large numbers of inflammatory DCs (Rescigno and Di Sabatino, 
2009; Zaba et al., 2009) that can modify the local immune environment by 
secreting proinflammatory cytokines and chemokines (Connolly et al., 2009; 
Weber et al., 2011), which cause direct tissue damage due to production of 
TNFα and inducible nitric oxide synthases (iNOS/NOS). These cells are de-
signated as TNF/iNOS producing dendritic cells (Tip-DCs) (Serbina et al., 
2003). This term has been extended to all inflammatory monocyte-derived DCs. 
Another interesting subtype of DCs are the Langerhans cells (LC), which 
populate the epidermal layer of the skin and can migrate to lymph nodes to 
present antigens (Schuler and Steinman, 1985; Wilson and Villadangos, 2004). 
However, unlike conventional DCs, they are generated from embryonic pre-
cursor cells that are recruited to the skin before birth and are maintained 
throughout life (Chang-Rodriguez et al., 2005; Chorro et al., 2009). LCs 
mediate contact-hypersensitivity responses (Kaplan et al., 2005), skin anti-
microbial immunity and play a role in the induction of tolerance to peripheral 
antigens (Merad et al., 2008). 
DCs can be easily generated from monocytes in vitro in the presence of GM-
CSF and IL-4. In the presence of GM-CSF, only macrophages are generated 
(Sallusto and Lanzavecchia, 1994). These in vitro generated cells are called 
monocyte-derived DCs and monocyte-derived macrophages. Monocyte-derived 
DCs are at immature state and can be matured by stimulation with pro-
inflammatory cytokines or microbial products. In vitro generated monocyte-
derived DCs are widely used as a substitute for in vivo DCs as they are easy to 
generate in large numbers compared with separating infrequent DCs from 
blood. Although in vitro systems are very widely used, the in vivo equivalent 
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has been difficult to identify, as GM-CSF driven cells do not exactly resemble 
the DCs identified in vivo. It has been suggested that culturing monocytes with 
GM-CSF and IL-4 generates dermal CD1a+ cDCs (Sallusto and Lanzavecchia, 
1994; Grassi et al., 1998; Palucka et al., 1998; Merad et al., 2013). 
 
 
2.2. Epigenetics 
Epigenetics is the study of changes that regulate gene expression without 
affecting the DNA sequence. Epigenetics aims to clarify how a limited number 
of genes (approximately 21000) (Pennisi, 2012) can define differentiation into 
specific cell types. The category of epigenetics consists of several sub-cate-
gories, including histone modifications, DNA methylation and microRNAs 
(miRNA) (Table 1). As miRNA expression profiles are not inherited to the 
daughter cell and are controlled through similar mechanisms to mRNA ex-
pression, their inclusion in the epigenetics field is still being questioned. 
Epigenetic control is important in a wide variety of processes, including the cell 
cycle, development, X chromosome inactivation, imprinting and response to 
environmental and biological modifications and ageing (Brooks et al., 2010).  
 
 
Table 1. Epigenetic modifications and the correspondent enzymes 
Epigenetic 
modification 
Best known types Location of 
action 
Enzymes 
DNA methylation 5-methylcytosine 
5- hydroxymethylcytosine 
CpG 
dinucleotide 
DNMT 
TET 
Histone 
modifications 
Acetylation of histone tails 
Methylation of histone tails 
N-terminal tails 
of histones 
HAT 
HMT 
Non-coding RNAs miRNAs Complementary 
target mRNA 
Pol II, Drosha,  
Dicer, Ago 
 
 
2.3.1. Histone posttranslational modifications 
In the nucleus, genomic DNA is complexed with several classes of chromo-
somal proteins and packed into chromatin. Basic chromosomal proteins, histo-
nes, form a nucleosome that consists of two copies of each core histone, H2A, 
H2B, H3 and H4 (Figure 2). Nucleosomes consisting of 146 bp of DNA 
wrapped around a histone octamer are the fundamental structural units of 
chromatin (Patel and Wang, 2013). The fifth histone, H1, binds to DNA at the 
intranucleosomal spacer region and thereby further packs nucleosomes into a 
high-order structure (Woodcock et al., 2006). Histones are proteins that have 
protruding N-terminal tails, which can influence interactions with other nucleo-
somes and other non-histone regulatory factors (Patel and Wang, 2013). Several 
amino acid residues within histone tails and the histone can be modified by 
different post-translational modifications, including methylation, acetylation, 
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phosphorylation, ubiquitination, sumoylation, citrullination, ribosylation and 
proline isomerisation (Figure 2) (Lee et al., 2013). Histone modifications are 
dynamic and influence several cellular processes, including transcription, repli-
cation, DNA repair and cell cycle progression (Ehrenhofer-Murray, 2004; 
Cosgrove and Wolberger, 2005; Shilatifard, 2006; Groth et al., 2007; Kou-
zarides, 2007; Li et al., 2007).  
 
 
 
 
 
 
 
 
Figure 2. Post-translational modifications on histone tails. N-terminal tails of histones 
(H2A, H2B, H3, H4) are modified. Ac: acetyl group, Me: methyl group, P: phosphate 
group. Modified from (Lee et al., 2013). 
 
 
Two of the best-characterised histone modifications are histone methylation and 
histone acetylation. Histone acetylation is almost always associated with active 
transcription. It is catalysed by histone acetyltransferases (HATs) and is re-
versed by histone deacetylases (HDACs). Thus, the cellular level of histone 
acetylation is determined by counteraction between HATs and HDACs. In the 
acetylation reaction, the acetyl group is carried over from acetyl-CoA to a lysine 
residue by HAT, which leads to chromatin decondensation and transcription 
activation (Marmorstein and Roth, 2001). On the contrary, HDACs remove 
acetyl group from histones, which leads to formation of heterochromatin and 
transcription repression.  
Histones can be methylated at lysine or arginine residues by histone methyl-
transferases (HMTs) (Shilatifard, 2006; Kouzarides, 2007) or protein arginine 
methyltrasferases (PRMTs) (Wolf, 2009), respectively. Lysines are methylated 
by the SET-domain containing proteins (Rea et al., 2000) and DOT1-like 
proteins (Feng et al., 2002). Histone-related lysine demethylation is carried out 
by lysine-specific demethylase 1 (LSD1) and members of the Jumonji C (JmjC) 
protein family (Rice et al., 2003). LSD1 carries out only mono- and di-
methylated substrate demethylation, whereas the JmjC family members can also 
demethylate trimethylated lysines (Klose and Zhang, 2007; Shi, 2007).  
Epigenetic regulation of chromatin structure is a complex process as it is 
regulated by different grades of modifications at lysine and arginine residues. 
Methylation of histone H3 at lysine 4 (H3K4), lysine 36 (H3K36) and lysine 79 
(H3K79) results in transcriptional activation, whereas methylation of histone 
H3 at lysine 9 (H3K9), lysine 27 (H3K27) and histone H4 at lysine 20 (H4K20) 
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is associated with transcriptional repression (Wu et al., 2007; Hublitz et al., 
2009). Complexity is added because methylation groups can be inserted in 
mono-, di- or trimethyl forms for lysines and mono- or dimethyl forms for 
arginines. The potential to activate or repress transcription is also determined by 
the genomic context. For example, di- and tri-methylation at H3K9 has an 
activation potential when at the coding regions and a negative potential when at 
the promoter regions (Vakoc et al., 2005).  
 
 
2.2.2. DNA methylation 
DNA methylation is the best-characterised chemical modification of chromatin. 
DNA methylation is a covalent addition of a methyl group to the fifth carbon of 
the cytosine ring to form 5-methylcytosine (5-mC)(Klose and Bird, 2006). DNA 
methylation mainly occurs in the context of CpG dinucleotides, although there 
is also evidence that methylation can be found outside of CpG context in em-
bryonic stem cells (Lister and Ecker, 2009; Yan et al., 2011). There are appro-
ximately 30 million CpG dinucleotides in the human genome that can be in 
methylated or unmethylated state (Cocozza et al., 2011). Up to 80% of the total 
number of CpG sites in the genome are methylated (Lister et al., 2009). CpG 
dinucleotides are not distributed uniformly along mammalian genomes; CpG 
sites are found in higher densities in gene-rich regions compared with gene-poor 
regions (Weber et al., 2005).  
 
 
 
Figure 3. DNA methylation. DNA methylation occurs in the context of CpG dinucleo-
tides. Many genes have upstream CG-rich regions called CpG islands. DNA methy-
lation on CpG islands (marked with red dots) represses gene expression. 
 
 
There are dense CpG rich areas at the promoters of more than a half of all 
genes. These areas, called CpG islands, are usually unmethylated (Figure 3) 
(Suzuki and Bird, 2008; Cedar and Bergman, 2009). Approximately 60% of 
gene promoters have CpG islands, including most housekeeping genes and half 
of the tissue-specific genes (Cheong et al., 2006; Deaton and Bird, 2011). CpG 
islands are approximately 0.5–2 kb long DNA sequences, with a CG content 
greater than 55%. Methylation of promoter CpG islands leads to gene inacti-
vation by allowing the binding of repressors and alteration of the DNA confor-
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mation and local histone structures (Meehan et al., 1992; Ng and Bird, 1999; 
Valinluck et al., 2004; Cedar and Bergman, 2009). Although it is known that 
methylation in promoters suppresses gene expression, the role of methylation in 
gene bodies is less clear and requires further investigation (Lorincz et al., 2004; 
Flanagan and Wild, 2007; Cokus et al., 2008; Ball et al., 2009; Rauch et al., 
2009). DNA methylation plays a vital role in several normal cellular functions 
and in a wide variety of pathological functions, including cancer (Jones and 
Baylin, 2007), imprinting disorders (Feinberg, 2007; Jones and Baylin, 2007) 
and even in the development of neuropsychiatric phenotypes (Mill et al., 2008).  
DNA methylation is carried out by the DNA methyltransferase (DNMT) 
family members, DNMT1, DNMT3A, DNMT3B and DNMT3L (Table 2) 
(Denis et al., 2011; Arand et al., 2012). These enzymes function by transferring 
a methyl group from S-adenosyl-L-methionine (SAM) to deoxycytosine. SAM 
is a modified amino acid that is produced in the carbon metabolism pathway. 
The process is reversed by DNA demethylases (Auclair and Weber, 2012). The 
transmission of DNA methylation patterns to daughter cells during cellular 
replication is executed by DNMT1, which methylates the nascent hemi-
methylated strand after DNA synthesis and prevents passive demethylation 
during cell division (Denis et al., 2011). DNMT1 deficiency leads to chromo-
somal instability and DNA repair defects (Kim et al., 2004). It also has a key 
function maintaining stem cells; DNMT1 disruption leads to instability of the 
stem cell pool (Trowbridge et al., 2009). Enzymes DNMT3A and DNMT3B are 
responsible for de novo methylation; they are capable of methylating both un-
modified cytosines and hemimethylated cytosines, producing new methylation 
patterns (Gowher and Jeltsch, 2001). The last member of the DNMT family is 
catalytically inactive DNMT3L, which is important in de novo methylation and 
imprinting. DNMT3L reorganises DNMT3A and DNMT3B complexes into 
defined sub-complexes that have a higher affinity to SAM, increased catalytic 
properties and higher processivity (Holz-Schietinger and Reich, 2010; Denis et 
al., 2011).  
 
 
Table 2. DNA methyltransferases and their role in DNA methylation 
DNA 
methyltransferase 
Role in DNA methylation Preference 
DNMT1 Maintenance  Hemimethylated DNA 
DNMT3A De novo methylation Un- and hemimethylated DNA 
DNMT3B De novo methylation Un-and hemimethylated DNA 
DNMT3L Imprinting, enhances 
methylation on DNMT3s 
Non-catalytic 
 
 
While 5-mC is the predominant epigenetic marker in higher eukaryots, it can be 
further oxidised to 5-hydroxymethylcytosine (5-hmC) by the Ten-11 trans-
location family proteins (TET1–3) (Laird et al., 2013). It is considered an inter-
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mediate in DNA demethylation pathway (Wu and Zhang, 2011), but whether its 
role is passive or active still needs to be confirmed. The demethylation pathway 
can also further oxidise 5-hmC to 5-formylcytosine (5-fC) and 5-carbo-
xylcytosine (5-caC). Many of the commonly used assays to measure DNA 
methylation level cannot distinguish between 5-mC and 5-hmC, although the 
level of 5-hmC in genome is approximately 10% of measured 5-mC and 
approximately 0.4% of all cytosines (Branco et al., 2011).  
Methylation has been extensively studied (Fernandez et al., 2012), and it has 
been shown that differentiated cell types have specifically methylated CpG sites 
(Ji et al., 2010; Bocker et al., 2011; Calvanese et al., 2011). There is also 
growing evidence that DNA methylation plays a pivotal role in several 
pathological processes, including cancer (Kriaucionis and Bird, 2003; Feinberg, 
2007; Jones and Baylin, 2007; Richardson, 2007; Urdinguio et al., 2009; 
Rakyan et al., 2011). In addition, multiple age-related methylation changes have 
been reported in multiple tissues and organisms (De Haan and Gerrits, 2007; 
Gronniger et al., 2010; Rakyan et al., 2010; Teschendorff et al., 2010; Bocker 
et al., 2011; Bocklandt et al., 2011).  
Many different processes in mononuclear phagocytes are regulated or tuned 
through epigenetic mechanisms. For example, in monocytes the production of 
pro-inflammatory cytokine IL-1β is regulated through DNA methylation (Wessels 
et al., 2010). In macrophages, histone modifications are involved in the pro-
duction of pro-inflammatory cytokines and polarisation towards M1 or M2 
subtypes (Medzhitov and Horng, 2009; Takeuch and Akira, 2011). In monocyte 
differentiation to DCs, an increase in DC-SIGN (CD209) expression is correlated 
with the loss of DNA methylation and the acquisition of active histone modifi-
cations instead of repressive histone modifications. In another example, the 
reduction of CD14 expression in monocyte-derived dendritic cells is correlated 
with the loss of active histone modifications (Bullwinkel et al., 2011).  
 
2.2.3. MicroRNAs 
miRNAs are small (~22 nucleotides) non-coding RNAs that regulate target gene 
expression by fine-tuning rather than completely shutting down mRNA 
translation in cells (Guo et al., 2010). They can act by directly binding to their 
target sequence in the 3'UTR, forming degradable double-stranded mRNA, or 
through the formation of a RNA-induced silencing complex (RISC) (Bartel, 
2004). miRNAs play a crucial role in several biological processes, including 
cell proliferation, differentiation, development, apoptosis and metabolism 
(Bushati and Cohen, 2007). To date, more than 2000 mature miRNAs have 
been described in humans (miRNA registry in http://www.mirbase.org/). 
miRNAs have numerous roles in eukaryotes, including the regulation of 
immune responses. In addition to their intracellular location, miRNAs have 
been found in various body fluids, including serum (Chen et al., 2008; Gilad et 
al., 2008; Lawrie et al., 2008), plasma (Mitchell et al., 2008), saliva (Park et 
al., 2009), urine (Hanke et al., 2010) and milk (Chen et al., 2010; Kosaka et al., 
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2010). miRNA expression patterns are significantly altered in pathological 
conditions such as cancer, diabetes and tissue injury (Zen and Zhang, 2010).  
miRNA biogenesis is a complex process involving several enzymes. miRNA 
genes can be located in the introns of protein-coding genes, but many are also 
derived from independent transcriptional units (Rodriguez et al., 2004). 
miRNAs are transcribed as long primary transcripts (pri-miRNAs) containing 
one or several miRNA-encoding hairpin structures (Figure 4) (Lee et al., 2004). 
Pri-miRNA is processed to precursor miRNA (pre-miRNA), which is then 
exported to the cytosol by Exportin-5. In the cytosol, pre-miRNA is further 
processed by Dicer to a double-stranded RNA duplex containing mature 
miRNA and its antisense strand (Kim et al., 2009). In the Dicer cleavage 
process, miRNA is coupled with RISC, which directs RISC to its target mRNA 
through partial sequence complementarity (Thieme et al., 2012). The RISC 
complex mediates the inhibition of translation and/or deadenylation and 
degradation of mRNA. miRNAs target the 3'UTR of mRNA, as actively 
translating ribosomes abolish the binding of the RISC complex to the coding 
region (Bartel, 2004; Kim, 2005; Chi et al., 2009). Each miRNA is predicted to 
target many mRNAs, and several miRNAs can control one mRNA at the same 
time. miRNAs can also target transcription factors, which adds complexity to 
their regulatory functions (Xiao and Rajewsky, 2009). Under certain conditions 
there is evidence that miRNAs can upregulate the expression of target genes 
(Vasudevan et al., 2007) and directly interfere with gene transcription (Kim et 
al., 2008); they can also be imported from the cytoplasm to the nucleus to 
regulate their own expression (Chen et al., 2012). miRNAs are secreted into the 
extracellular space, where they function as signalling molecules and mediate 
communication between cells (Chen et al., 2012). For instance, it has been 
demonstrated that miRNAs can serve as ligands to Toll-like receptors (Fabbri et 
al., 2012; Lehmann et al., 2012), which normally mediate the host immune 
response to invading pathogens. 
Several miRNAs regulate the differentiation and function of MPS cells 
(Xiao et al., 2007; Lodish et al., 2008; O'Connell et al., 2010). Two well-
studied miRNAs that have roles in the immune system are miR-155 and miR-
146a; both have several functions in macrophages and DCs. miR-155 acts 
mainly as an activator and miR-146 as a suppressor of immune responses. miR-
155 controls T cell differentiation and germinal centre reactions (Thai et al., 
2007). In macrophages, miR-155 is involved in macrophage polarisation and 
apoptosis (O'Connell et al., 2007; Cai et al., 2012; Ghorpade et al., 2012; Koch 
et al., 2012). In pDCs, it targets transforming growth factor beta (TGF-β) 
activated kinase 1-binding protein 2, regulating IFN-α/β expression and DCs 
TLR/IL-1 inflammatory pathways related to monocyte-derived DCs (Ceppi et 
al., 2009; Zawada et al., 2011). In peripheral blood monocytes, miR-146 
controls the response to inflammatory challenge by targeting RelB, a member of 
the NF-κB/Rel family (Etzrodt et al., 2012). 
 
22 
 
 
Figure 4. The miRNA processing pathway. The primary miRNA transcript (pri-
miRNA) is transcribed by RNA polymerase II and then cleaved to the pre-miRNA by 
the microprocessor protein complex Drosha in the nucleus. Pre-miRNA is exported 
from the nucleus by Exportin-5–Ran-GTP (EXP5). In the cytoplasm, the functional 
strand of the mature miRNA, together with Argonaute (AGO2) proteins, is loaded into 
the RNA-induced silencing complex (RISC), where it guides RISC to silence target 
mRNAs. Modified from (Cullen, 2006; Winter et al., 2009). 
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2.3. Ageing in the immune system 
Ageing is a complex physiological process that is contributed to by the accu-
mulation and progression of several degenerative processes, including cellular 
senescence, DNA repair and oxidative stress (Vijg and Campisi, 2008). Ageing 
is associated with gradual declines in mechanisms that maintain tissue structure 
and function. It is a process of physical, psychological and social changes that 
are associated with characteristic epigenetic changes, including DNA methy-
lation and histone post-translational modifications (Krishnamoorthy et al., 
2006; Fraga and Esteller, 2007; Oberdoerffer and Sinclair, 2007). 
Many clinical disorders associated with ageing can be ascribed to the 
immune system; ageing is described as overall deterioration of immune system 
(DeVeale et al., 2004). Both adaptive and innate immune systems are affected 
in the ageing process. In the adaptive immune system, ageing is associated with 
a reduced proportion of naïve T cells compared to their memory counterparts 
(Chakravarti and Abraham, 1999). This is mainly the result of thymic in-
volution, which leads to a reduction of naïve T cells, and lifelong accumulating 
exposure to foreign antigens, which leads to an increase of activated memory T 
cells (Jamieson et al., 1999; Koch et al., 2008). In addition to changes in 
numbers and composition, immune cells also acquire diminished proliferative 
responses, altered cytokine production and responsiveness, aberrant phenotypes, 
decreased antigen recognition and aberrations in signal transduction (Chakra-
varti and Abraham, 1999; Miller, 2000; Weksler, 2000; Szakal et al., 2002; 
McGlauchlen and Vogel, 2003; Gupta et al., 2004; Shilatifard, 2006; Koch et 
al., 2008). In antibody-mediated immune responses, the quantity and production 
of serum antibodies declines with age (Weksler, 2000). The antibody repertoire 
of elderly individuals is composed of different isotypes and has reduced affinity 
compared to that of young individuals (Weksler, 2000; McGlauchlen and 
Vogel, 2003). 
Unlike the adaptive immune system, which exhibits reduced functions with 
age, the impairment of the innate immune system results in elevated level of 
basal inflammation. This is also referred as inflamm-ageing and is characterised 
as having elevated levels of circulating pro-inflammatory cytokines (IL-1β, IL-
6, IL-8, TNFα, IL-15) and reduced levels of anti-inflammatory cytokines (IL-
10) (Franceschi et al., 2007). Whereby, centenarians have been shown to 
maintain the cytokine profile of younger adults (Di Bona et al., 2009). Ageing 
exhibits harmful effects on the cells of the innate immune system; the phago-
cytic capacity of neutrophils, reactive oxygen intermediate synthesis and intra-
cellular killing efficiency are impaired (Wenisch et al., 2000; Fulop et al., 
2004), although the number of neutrophils does not change in the elderly 
(Gomez et al., 2008). NK cell cytotoxicity and cytokines and chemokine 
production are also dysfunctional (Mariani et al., 2002; Mocchegiani et al., 
2003). The absolute numbers of monocytes are not changed during ageing, but 
the subpopulation proportions are changed; CD16+ monocyte numbers are 
increased and CD16- monocyte numbers are decreased (Nyugen et al., 2010). 
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Nevertheless, monocytes display age-related alterations in their function. The 
ability of monocytes to activate the TLR pathway or to express cytokines is 
often impaired; the expression of TLR1 and TLR2 increases with age, whereas 
the functions of TLR4 and TLR8 decrease (van Duin et al., 2007; Agarwal and 
Busse, 2010). Although the number of macrophage precursors in bone marrow 
is lower, the macrophage number, size, DNA content and expression of cell-
surface markers are unaltered (Sebastian et al., 2005). The ability of macro-
phages to migrate towards the site of infection is declined, which may contri-
bute to a delayed immune response (Fietta et al., 1993). In addition, intra-
cellular killing of pathogens is decreased due to a lower production rate of 
reactive oxygen intermediates (Ding et al., 1994). The number of DCs do not 
change during ageing (Agrawal et al., 2007), but in elderly people, their ability 
to activate naïve T cells is decreased; this has been observed in  both monocyte-
derived DC and pDCs (Agrawal et al., 2008; Agrawal et al., 2012). Endo-
cytosis, chemotaxis and the production of IL-12 are also impaired (Agrawal et 
al., 2012). DCs also contribute to the constant inflammatory status of elderly by 
increasing the production of IL-6 and TNF-α without specific stimulation 
signals (Agrawal and Gupta, 2011). 
During the lifetime epigenome can be influenced by genetic, stochastic 
(random mutation) and systematic (response to environmental changes) factors. 
It is well established that some genes that are in early life epigenetically down-
regulated become activated in ageing (Salpea et al., 2012). Genetically identical 
twins have indistinguishable epigenome early in life, whereas older individuals 
exhibit significant differences in their epigenetic patterns (Fraga et al., 2005). A 
gradual age-associated DNA hypomethylation has been described in several 
genomic copartments, including promoters, exons, introns and intergenic 
regions (Heyn et al., 2012). In addition to hypomethylation, also hypermethy-
lation of specific promoters across lifespan has been described, including also 
estrogen receptor, genes involved in DNA binding and regulation of 
transcription (Post et al., 1999; Oakes et al., 2003). Ageing is characterised by 
changes in type and combinations of histone modifications and gradual 
reduction of histone level that drastically affects chromatin structure (D'Aquila 
et al., 2012). In addition, the activity of several enzymes responsible for the 
establishment and removal of epigenetic marks is changed in ageing. For 
example, the activities of DNMT1 and DNMT3A (Casillas et al., 2003) and 
deacetylase SIRT1 (Marton et al., 2010) are reduced and the activities of 
demethylases Jmjd3 and Jarid1b are increased (Jung et al., 2010; Nijwening et 
al., 2011). All this contributes to changed epigenetic patterns and thereby 
changed gene expression facilitating in ageing phenotype.  
In sum, ageing-associated changes in the immune system encompass both 
the number of immune cells and their functionality. These alterations lead to 
cumulative effects in the immune response, resulting in chronic inflammation 
and contributing to age-related diseases, including infections, cardiovascular 
diseases and cancers.  
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3. AIMS OF THE STUDY 
The aims of this study were: 
1. To compare the histone modification and gene expression profiles of human 
monocytes, monocyte-derived DCs and macrophages. 
2. To identify microRNA expression profiles of human monocytes, monocyte-
derived DCs and macrophages, to find DC-specific microRNAs and study 
their functional role. 
3. To study changes in DNA methylation, which occur in human monocytes 
during ageing. 
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4. MATERIALS AND METHODS 
4.1. Monocyte extraction and cell culture  
The whole blood and buffy coats were obtained from donors at the Estonian 
Genome Center and Tartu University Hospital’s Blood Center. All participants 
were older than 18 years and signed a written informed consent form. Studies 
were approved by the Ethics Review Committee on Human Research of the 
University of Tartu, Estonia (protocol numbers 170/T-7; 182/M-1 and 206/T-4). 
PBMCs were prepared by density gradient centrifugation on Ficoll-PaqueTM 
PLUS (GE Healthcare Bio-Sciences AB). Monocytes were enriched using 
magnetically activated cell sorting (MACS; Miltenyi Biotec) with anti-CD14-
conjugated magnetic microbeads and either a manual or automatic separation 
system (Miltenyi Biotech). Monocytes were differentiated into MFs using  
50 ng/ml GM-CSF and into DCs using 50 ng/ml GM-CSF and 25 ng/ml IL-4 
(both from PeproTech); differentiation was performed for 6 days at 1 million 
cells/ml in RPMI 1640 supplemented with 2 mM L-glutamine, 100 U/ml peni-
cillin, 100 μg/ml streptomycin and 10% FCS (all from PAA). The expression 
of surface proteins on monocytes, macrophages and DCs was analysed using 
fluorescence-conjugated antibodies to CD14, DC-SIGN, CD80 and CD83 
(Miltenyi) and FACSCalibur (BD Biosciences) was used to confirm the charac-
teristic phenotypes. 
 
 
4.2. Quantitative real-time PCR 
For quantitative mRNA RT-PCR, cDNA was synthesised using oligo-dT and 
SuperScript III Reverse Transcriptase (Invitrogen). Quantitative PCR was 
carried out using Maxima SYBR green/Rox Master Mix (Fermentas). miRNA 
expression was analysed using Taqman MicroRNA Assays, a TaqMan 
MicroRNA Reverse Transcription Kit (Applied Biosystems) and 5X HOT 
FIREPol Probe RT-PCR Mix Plus (Solis Biodyne). All primers used in the 
study are listed in Table 3. All RT-PCRs were carried out using ABI Prism 
7900; the relative gene expression levels were calculated using the comparative 
Ct (∆∆Ct) method (Applied Biosystems).  
 
 
4.3. Gene expression arrays 
RNA was extracted using a miRNeasy Mini Kit (Qiagen) or the Trizol reagent 
(Invitrogen) combined with a RNeasy Mini Kit (Qiagen). The concentration of 
RNA was assessed with a NanoDrop ND-1000 spectrophotometer (NanoDrop 
Technologies), and the quality was assessed with an Agilent RNA 6000 Nano Kit 
and an Agilent 2100 Bioanalyzer (Agilent Technologies). RNA was amplified 
and labelled using an Illumina TotalPrep RNA Amplification Kit (Ambion Inc.) 
or a TargetAmp-Nano Labeling Kit (Epicentre). mRNA and miRNA profiling 
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was carried out in the Core Facility at the Department of Biotechnology, Uni-
versity of Tartu using Illumina Human-6 v2 BeadChips and Illumina miRNA 
Universal-16 BeadChips (miRBase version 12.0) (both from Illumina) 
respectively. The data were analysed with BeadStudio Gene Expression Module 
v3.3.7 (Illumina) using Illumina’s custom rank invariant method or average 
normalisation. Microarray data are available in the ArrayExpress databank with 
accession numbers E-TABM-976 and E-TABM-968. 
 
 
4.4. Transfection of anti-miR inhibitors and siRNAs 
For miRNA inhibition experiments, pre-designed anti-miRNA inhibitors, 
locked nucleic acid (LNA)-based miR-511 inhibitor and unlabelled control A 
(Exiqon) were used. For DICER inhibition, Silencer Select Validated DICER1 
siRNAs (s23754, s23756) and respective negative controls (Applied Bio-
systems) were used. All transfections were carried out at the concentration of 
120 nM siRNA or miRNA inhibitors using 3 µl of siPORT NeoFX Transfection 
agent for 106 cells/1 ml medium (Applied Biosystems). After the transfection 
procedure, monocytes were differentiated as usual (Paragraph 0). Transfection 
efficiency was controlled by fluorescence microscopy of separate transfections 
using Cy3-labelled negative control miRNA inhibitors or negative control 
siRNAs; efficiency was estimated to be between 90–100%.  
 
 
4.5. Chromatin immunoprecipitation (ChIP) and  
ChIP-on-ChIP assay 
ChIP with some modifications was performed according to the Upstate Chro-
matin Immunoprecipitation Assay protocol (Upstate). Briefly, formaldehyde 
crosslinking was carried out in PBS containing 1% formaldehyde and 0.5 mM 
EGTA with the density of 7x107 cells in 70 ml. To process all samples in 
parallel, monocyte samples were crosslinked, lysed and subjected to sonication 
on day one and the lysates were kept at 4ºC until macrophage and DC samples 
were collected. Approximately of 1x107 cells, 30 µl of packed protein G 
sepharose beads (GE Healthcare; pre-absorbed with 100 µg/ml BSA and 500 
µg/ml of sheared salmon sperm DNA) and 4 µg of H3 (Abcam, ab1791), 
H3K4me3 (Abcam, ab8580), H3K27me3 (Upstate, 07–449) or AcH3 (Upstate, 
06–599) antibodies were used in each immunoprecipitation. 
DNA probes from ChIP were amplified using the GenomePlex Complete 
Whole Genome Amplification (WGA) Kit and reamplified using the Genome-
Plex WGA Reamplification Kit (both from Sigma-Aldrich). Sample labelling, 
hybridisation and data extraction was performed by NimbleGen Systems using 
385K RefSeq Promoters array set. The NimbleGen RefSeq Promoter array data 
are available at ArrayExpress databank with accession number E-TABM-979. 
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4.6. DNA isolation and DNA methylation determination 
Genomic DNA was isolated from cell pellets using a QIAmp DNA Micro Kit 
(Qiagen) according to the manufacturer's protocol. DNA concentration was 
measured with NanoDrop ND-1000 spectrophotometry. Approximately 500 ng 
of genomic DNA was bisulfite-converted with an EZ-96 DNA Methylation Kit 
(Zymo Research Corporation), according to the manufacturer's protocol. DNA 
methylation analysis was performed using Infinium Human Methylation 450K 
bead chip technology (Illumina). 
Quantitative analyse of DNA methylation was determined using Sequenom’s 
EpiTYPER T Complete Reagent Set (Sequenom, Inc.). DNA was amplified 
using bisulfite-converted DNA, Hot Start DNA Polymerase (Solis BioDyne) 
and primers, according to the EpiTYPER protocol. Primers were designed with 
Sequenom’s EpiDesigner program and are listed in Table 3. 
 
 
4.7. Cloning and Luciferase assay 
For the Luciferase (LUC) assay, the following 3'UTR fragments of TLR4 
(NM_138554.3) were used: TLR4-I (3096–3736), TLR4-II (4588–5000) and 
TLR4-III (5028–5384). The fragments were PCR amplified, digested with FseI 
(New England Biolabs) and XbaI (Fermentas) and inserted into the same 
restriction sites of pGL3-Control (Promega) downstream the LU coding region. 
The cloned plasmids were verified by sequencing. The cloning primers are 
listed in Table 3. 
For Luciferase assay 8 × 104 HEK293 cells were plated into 24-well plates 
and transfected after 24 h with 20 ng of renilla encoding pRL-TK (Promega), 
100 ng of the pGL3-3'UTR reporters and with either 50 nM of pre-miR-511 
precursor or the FAM labelled pre-miR-control (Applied Biosystems); the 
siPORT NeoFX Transfection Agent (Applied Biosystems) was used in these 
experiments. Cells were harvested after 48 h or 96 h in contact inhibition con-
ditions (Vasudevan et al., 2007) and analysed using the Promega dual luciferase 
assay. Luminescence was counted using a Wallac 1420 (Perkin Elmer). 
 
 
4.8. Protein expression 
For western blot analyses, rabbit polyclonal anti-human TLR4 (sc-10741, Santa 
Cruz Biotec) in 2% milk, mouse monoclonal anti-human GAPDH (ab8245, 
Abcam) in 5% milk and DICER1 (ab14601 Abcam) in 5% milk were used. 
Signals were detected with an ECL Advance Western Blotting Detection Kit 
(GE Healthcare) and captured and quantified using an ImageQuantTM-RT ECL 
image analysis system. For FACS, fluorescence-conjugated antibodies to CD83, 
DC-SIGN, CD86 (BD Biosciences), CD14 and HLA-DR (Miltenyi Biotec) 
were used with the FACSCalibur system (BD Biosciences). Data were analysed 
and visualised with FlowJo v. 7.6. 
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4.9. Primer sequences 
The sequences of primers (TAG Copenhagen, Copenhagen, Denmark) used in 
the study are listed in Table 3. 
 
 
Table 3. Primers used in the study together with the corresponding sequences, genes 
and applications used 
Oligo name Sequence Gene Application 
DICER F GGCTGTAAAGTACGACTACC Dicer qPCR 
DICER R GATCTCCTAAGCTCAGAATCC Dicer qPCR 
TLR4-1 F ATCCCCTGAGGCATTTAGGC TLR4 qPCR 
TLR4-1 R TCAATTGTCTGGATTTCACACCTG TLR4 qPCR 
TLR4-2 F TCCCTCCCCTGTACCCTTCT TLR4 qPCR 
TLR4-2 R AGCATTGCCCAACAGGAAAC TLR4 qPCR 
TLR4-3 F ATCCCTGGGTGTGTTTCCAT TLR4 qPCR 
TLR4-3 R TGCGGACACACACACTTTCA TLR4 qPCR 
HPRT F GACTTTGCTTTCCTTGGTCAGG TLR4 qPCR 
HPRT R AGTCTGGCTTATATCCAACACTTCG TLR4 qPCR 
TLR4-I F ATATCTAGAAAAGACAGAGAAAA CAGAAAGAGACA TLR4 Cloning 
TLR4-I R ATAGGC CGGCCTTCCTTCCTGCCTCTAGCCC TLR4 Cloning 
TLR4-II F ATATCTAGACCCGGAGGCCAT TATGCTAT TLR4 Cloning 
TLR4-II R ATAGGCCGGCCCAATTTGATGAGTT TAGACATAGTCAC TLR4 Cloning 
TLR4-III F ATATCTAGAATATCAATTATGTCTG AATGAAGCTAT TLR4 Cloning 
TLR4-III R ATAGGCCGGCCAGAGAACTCATCTC AAACAGCC TLR4 Cloning 
NRP1 T7 F 
 
AGGAAGAGAGTTGGGTTTTAGGTTA 
ATGTAGGTTG NRP1 Sequenom 
NRP1 T7 R 
CAGTAATACGACTCACTATAGGGAG 
AAGGCTACTATCCAACAAAACCCCA 
AATAAT 
NRP1 Sequenom 
NRXN2 T7 F AGGAAGAGAGGTTTAAGGAATTGGT 
TGGTAGGAAT 
NRXN2 Sequenom 
NRXN2 T7 R CAGTAATACGACTCACTATAGGGAG 
AAGGCTATATAAACCCCTCCACCTT 
ATACCC 
NRXN2 Sequenom 
miR-29b-2 T7 F 
5´_T7 F 
AGGAAGAGAGTTTGATGGGATTAAA 
TTTTGGAATA 
miR-29b-2 Sequenom 
miR-29b-2 T7 R 
5´_T7 F 
 
CAGTAATACGACTCACTATAGGGAG 
AAGGCTAAAAAAACAAAACACCC 
ACATACAC 
miR-29b-2 Sequenom 
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5. RESULTS 
5.1. Genome-wide promoter analysis  
of histone modifications (Ref. I) 
5.1.1. Genome-wide mRNA expression profiles 
As monocyte-derived DCs are the most common type of DCs used in immuno-
therapeutic approaches (Melief, 2008; Tyagi et al., 2009), we used in vitro 
differentiated human blood monocyte-derived DCs and macrophages in our 
analyses (Sallusto and Lanzavecchia, 1994). First, an Illumina Human-6 v2 
BeadChip array was carried out to obtain detailed mRNA transcription profiling. 
Overall, the gene expression profiles of monocytes, macrophages and DCs were 
similar. However, we found a significantly higher correlation between the 
expression profiles of macrophages and DCs than between the profiles of 
monocytes and macrophages or monocytes and DCs. A similar number of genes 
were upregulated in macrophages and DCs (1663 and 1630 genes; approximately 
8%) (Figure 5) and approximately the same proportion were downregulated 
during macrophage (1952; 9%) and DC (1654; 8%) differentiation. Most of the 
upregulated (1037) and downregulated (1328) genes in macrophage and DC 
populations overlapped, indicating a similarity between the two cell populations. 
 
 
 
Figure 5. Upregulated and downregulated genes in macrophages and DCs. 
 
 
According to the gene expression array, there are specific markers and cyto-
kines that are differentially expressed in the cell populations studied. For 
example, the monocyte population had very high expression of CD14, CCR2, 
CSF1R and SELL/CD62L mRNA, which were all downregulated after the 
differentiation to macrophages or DCs (Table 4). In contrast, two marker genes 
specific to the human CD16+ monocyte subpopulation, FCGR3A/CD16A and 
FCGR3B/CD16B, were expressed at low levels. In both macrophage and DC 
populations, we observed highly increased expression of surface markers 
TM7SF4/DC-STAMP and TREM2 and the chemokines CCL3 and CCL22. 
Despite large similarities between the expression profiles of macrophage and 
DC populations, there were many genes that were differentially expressed in 
these cell types. In DCs, several additional surface markers were strongly 
upregulated, such as CD209/DC-SIGN, SLAM and CD1 family genes, as well 
as the chemokines CCL2, CCL13, CCL17, CCL23 and CCL26.  
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The expression data showed that macrophages and DCs share a similar global 
mRNA expression pattern that is different from their monocyte precursors.  
 
 
Table 4. Selected marker and cytokine gene expression signals and their differential 
scores in monocytes and after differentiation to macrophages and dendritic cells 
Gene Monocyte Macrophage Dendritic cell 
 Signal Signal Score* Signal Score 
CD1A 226 160 -4 7934 48 
CD1B 34 794 9 11970 103 
CD1C 308 105 -16 4012 39 
CD4 1191 494 -26 452 -30 
CD14 13904 4056 -41 122 -77 
CD40 57 624 28 762 85 
CCL2 19 1542 6 1022 54 
CCL3 72 6355 49 3436 99 
CCL13 7 462 6 21325 103 
CCL17 1 65 21 19817 75 
CCL22 15 7026 124 14991 103 
CCL23 1 406 16 2200 18 
CCL26 14 13 0 2295 26 
CCR2 912 1 -26 2 -26 
CSF1R 11566 3911 -26 6423 -11 
LY9/SLAMF3 13 113 42 635 52 
SLAMF7 63 851 58 1226 76 
SLAMF8 52 2745 68 2182 98 
SLAMF9 11 469 108 217 55 
SELL/CD62L 2807 10 -77 7 -77 
DC-SIGN/CD209 46 798 28 8191 102 
DC-STAMP/TM7SF4 1 8783 125 3809 103 
TREM2 1 1810 123 2834 103 
*The Illumina BeadStudio differential expression score indicate a significant difference between 
expression levels. A differential score >13 correspond to a statistically significant change with a 
P-value less than 0.05. Positive values correspond to the upregulation of expression and negative 
values to downregulation. 
 
 
5.1.2. Histone modification patterns 
To explain the different gene expression patterns in monocytes, macrophages 
and DCs, we decided to investigate histone modifications and their correlation 
with gene expression profiles. The influence of histone modifications on gene 
expression profiles has been shown in different studies (Roh et al., 2006; 
Lehtonen et al., 2007; Araki et al., 2009; Wei et al., 2009; Karlic et al., 2010). 
We used a high-resolution promoter microarray screen with immunoprecipitated 
chromatin (ChIP-chip). In our study we used antibodies to different modifi-
cations of histone H3; H3K4me3 and AcH3, as active chromatin marks, and to 
H3K27me3, as an inactive chromatin mark. The immunoprecipitated material 
  
 
32 
was hybridised to the NimbleGen promoter array covering 19222 gene pro-
moters in the human genome, which overlap with 17289 genes on the Illumina 
Human-6 v2 BeadChip expression array.  
The most prevalent mark in the studied cell populations was H3K4me3, which 
was present on 45% of monocyte genes, 43% of macrophage genes and 37% of 
DC genes (Figure 6A). The AcH3 mark was found in the three cell subsets with 
nearly equal frequency and was present on 30–32% of the gene promoters. The 
H3K27me3 mark had the lowest frequency of the studied modifications; it was 
present on 23–27% of promoters. Notably, more than one third of gene promoters 
(36 to 39%) lacked the histone modifications studied here. As expected, the most 
prevalent combination of marks was the double H3K4me3/AcH3 (25–28%), 
whereas the combination of H3K4me3 and H3K27me3 was present on only 5–
6% of gene promoters (Figure 6A). A considerable proportion of genes (16–19%) 
were positive for the H3K27me3 modification alone.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Frequencies of the H3K4me3, AcH3 and H3K27me3 marks and their com-
binations in (A) all genes (B), transcriptionally active genes and (C) inactive gene pro-
moters. Frequencies of the modifications are shown as percentages in scaled circles 
positioned in the outer corners of the triangles. Frequencies of co‐occurring modifi-
cations are shown between them. “No mark” represents a lack of all the histone modi-
fications that were analysed in this study. 
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The H3K4me3 modification often overlaps with the AcH3 mark on active 
genes, but in combination with H3K27me3, it marks genes poised for either 
activation or repression (Bernstein et al., 2007).  Therefore, we analysed the 
presence of histone marks among a subset of transcriptionally active genes 
(Figure 6B). Similar to the data that includes all of the genes in the genome, the 
most common combination among expressed genes was the H3K4me3/AcH3 
modification, which was present in 33–38% of promoters. The double modi-
fication of H3K4me3 and H3K27me3, marking the so-called bivalent poised 
genes, was present in 4–5% of genes; however, a mark for silenced genes, 
H3K27me3 alone, was clearly decreased (9–12%) in the expressed genes. We 
noted that during the differentiation of monocytes to DCs, the proportion of 
genes with H3K4me3 alone decreased from 14% to 5%, in contrast to the AcH3 
mark, which slightly increased from 2% to 6% (Figure 6B). These changes, 
although to a lesser extent, also occurred in macrophage differentiation; 
H3K4me3 decreased to 10% and AcH3 increased to 3%. Modifications on 
transcriptionally inactive genes were clearly different; the main modification on 
these gene promoters was H3K27me3 alone (30–33%) or in combination with 
H3K4me3 (7–11%). Only 7% to 8% of genes had the combination of the 
H3K4me3 and AcH3 marks (Figure 6C).  
The most prevalent histone mark in monocytes, monocyte-derived macro-
phages and dendritic cells is H3K4me3, followed by AcH3 and then by 
H3K27me3. The most common combination was the H3K4me3/AcH3 modi-
fication. In addition, histone modification patterns can be correlated with gene 
activity; the most common combination among active genes was the H3K4me3/ 
AcH3 modification and among inactive genes H3K27me3 alone. 
 
 
5.1.3. Histone marks in differentiation 
As histone modifications are highly dynamic, we analysed their dynamics 
during the differentiation process from monocytes to macrophages and DCs. 
The mark characteristic for active genes, the double H3K4me3/AcH3, often 
persisted on genes throughout the differentiation process (Figure 7). However, 
we noted a striking decrease of H3K4me3 and AcH3 modifications when they 
occurred alone. The H3K4me3 mark was lost or turned into a double mark (by 
an additional acetylation) in 72% or 86% of corresponding genes in macro-
phages and DCs, respectively. Similarly, 84–85% of genes with the AcH3 mark 
alone lost this modification status during differentiation from monocytes. In 
contrast, the H3K27me3 modification alone was relatively stable, although less 
so when it occurred in combination with H3K4me3 (Figure 7). 
These results demonstrate the dynamic nature of histone modifications 
during differentiation and show that presence of the H3K4me3 and AcH3 
modifications alone leads to either a loss of these individual marks or a gain of 
the H3K4me3/AcH3 mark. 
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Figure 7. Dynamics of histone modifications and the combinations of modifications 
observed. Gene sets with indicated histone modifications present in monocytes (MO) 
were analysed further in macrophages (MFs) and DCs. The scale indicates the number 
of genes in each set in the monocyte population. 
 
 
5.1.4. Correlation of histone modifications and  
gene expression 
To study the correlation of histone modifications and gene expression profiles, 
we studied the promoters of several well-established marker genes, many of 
which are associated with macrophage and DC differentiation (Figure 8A). For 
example, the CD14 and CD4 genes had the double H3K4me3/AcH3 mark on 
their promoters in monocytes, where they are expressed at high levels, but they 
lost these marks during differentiation. CD8A and CD8B genes were not ex-
pressed in any of the cells studied and were marked by the repressive 
H3K27me3 modification. The gene encoding costimulatory ligand CD86 is 
relatively highly expressed in all three cell types and has the double 
H3K4me3/AcH3 mark but CD80 gene, which is expressed at lower level, was 
marked by AcH3 only. The highly expressed integrin marker ITGAM/CD11b 
had the H3K4me3 modification in monocytes and macrophages and acquired an 
AcH3 mark in DCs. The expression of ITGAL/CD11a decreased during diffe-
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rentiation and lost its H3K4me3 and AcH3 marks in DCs. Active H3K4me3/ 
AcH3 chromatin marks were also present on the integrin ITGAX/CD11c and 
SIRPA genes. 
 
 
 
 
 
Figure 8. Comparison of gene expression levels and H3K4me3, AcH3 and H3K27me3 
modifications among functional gene groups in monocytes, macrophages and DCs. 
Histone modifications and their correlation with expression levels in (A) individual 
genes of cell markers and genes involved in (B) antigen presentation or (C) phago-
cytosis. Colour scale indicates the expression level from no expression (blue) to high 
expression (red). Dark green represents presence of the modification and light green 
represents absence. 
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Phagocytosis and antigen presentation are the two most central functions of 
monocytes and monocyte-derived cells. Therefore, we studied the histone modi-
fications of genes involved in these two key categories of antigen-presenting 
cells, in correlation with their gene expression levels. Out of 15 genes as-
sociated with phagocytic function, the double H3K4me3/AcH3 mark was 
present on 11 promoters in monocytes, 8 promoters in macrophages and 6 pro-
moters in DC populations (Figure 8C). Most of the 37 genes associated with 
antigen presentation, including human leukocyte antigen (HLA) class I and 
class II, β2-microglobulin (B2M), proteasome-associated and peptide trans-
porter (TAP1 and TAP2), had the double H3K4me3/AcH3 mark on their 
promoters (Figure 8B). These data are in agreement with the general functio-
nality of antigen-presenting cells that is monocytes and macrophages are more 
active in phagocytic activities, whereas macrophages and DCs are more effi-
cient at antigen presentation.  
These data provide evidence that histone modifications correlate with gene 
activity and, more specifically, with the general functionality of the cells. 
 
 
5.2. MicroRNA expression profiles (Ref. II) 
 5.2.1. miRNA profiles  
The role of miRNAs in regulating immune cell differentiation and function has 
been described previously. To describe the expression and roles of recently 
described miRNAs, we differentiated human blood monocytes into DCs and 
macrophages and stimulated them, on day 6, with LPS, as a TLR4 ligand, and 
curdlan, as a Dectin-1 (CLEC7A) ligand. Total RNA was analysed on Illumina 
miRNA arrays containing probes for 858 human mature miRNAs, based on 
miRBase 12.0 (Griffiths-Jones et al., 2008). Altogether, 307 to 380 miRNAs 
were expressed; 39 miRNAs were upregulated and 10 were downregulated in 
immature or mature DCs and macrophages (Figure 9). The three most highly 
upregulated miRNAs in DCs and macrophages were miR-99b, miR-212 and 
miR-511. Some miRNAs were specific to DCs; for example miR-193b, miR-
125b and miR-99a, whereas others were more specific to macrophages; for 
example, miR-139-5p, miR-1 and miR-218. Changes in miRNA expression 
emerged mainly during differentiation and not in the stimulation process. After 
stimulation, a relatively small increase in expression was detected for 16 
miRNAs. No miRNAs specific to either LPS or curdlan stimulation were 
detected.  
Our data describes updated miRNA expression profiles of human mono-
cytes, monocyte-derived macrophages and DCs, including also miRNAs that 
were not reported in these cells earlier. 
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Figure 9. Monocytes (MOs), dendritic cells (DCs), and macrophages (MFs) have spe-
cific miRNA expression profiles. Heatmaps of miRNAs that are up- or downregulated 
(differential p>0.05) in DCs and/or macrophages compared to their levels in monocytes. 
miRNAs shown have an average expression level of over 100 in at least one condition. 
Each column represents expression levels of miRNA (shown right) in each sample 
(shown above). Log2 expression values for each miRNA are mean-centred across all the 
analysed miRNA expression values. The colour scale from green (lower) to red (higher) 
represents deviation from the mean (black). 
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5.2.2. Inhibition of miRNAs results in delayed differentiation 
phenotype of DCs 
To further prove that miRNAs are essential for DC differentiation, we carried 
out a siRNA knockdown of DICER1, a protein that is indispensable for miRNA 
processing (Perron and Provost, 2009) (Figure 4). The knockdown efficiency of 
DICER1 was approximately 50% (Figure 10A), and knockdown resulted in a 
lower protein level of DC-SIGN and a higher level of CD14 (Figure 10B), 
which is indicative of a delayed differentiation phenotype in DCs. To further 
show the effect of DICER1 knockdown on DC differentiation, the DC-
SIGN/CD14 ratios were calculated and found to be significantly different 
(Figure 10C).  
 
 
Figure 10. Reduced expression of DICER1 results in the downregulation of the DC-
specific surface marker, DC-SIGN. (A) Inhibition of DICER1 (si-DICER) is shown as 
an average mRNA expression level with S.E. of three different treatments normalised to 
an average of the negative controls (si-neg, which equals 1). (B) A histogram re-
presenting the geometric mean fluorescent intensities of the indicated surface molecules 
shown as a percentage of maximum in DICER1 and siRNA treated cells (filled grey) 
relative to control treated cells (black line). (C) Ratios of DC-SIGN and CD14 mean 
fluorescence intensity values were calculated and are shown relative to the control 
transfections (neg, adjusted to 1); data from four different donors are plotted and the p-
value was calculated using the Mann-Whitney test.  
 
 
Next, we investigated the impact of specific miRNAs on DC differentiation. We 
performed in vitro DC differentiation in the presence of sequence specific 
miRNA inhibitors of DC- and macrophage-specific miRNAs, miR-511 and 
miR-99b, and of a DC-specific miRNA, miR-193b (Figure 9). These miRNAs 
were selected for further analyses, because they had high expression values that 
were remarkably changed in the differentiation process. The transfection of 
miRNA inhibitors resulted in a 50–90% reduction in expression of specific 
miRNA (Figure 11A), which led to reduced DC-SIGN protein levels, especially 
in case of miR-511 and miR-99b (Figure 11B). The specific miRNA inhibitors 
did not influence the levels of two surface markers, CD14 and HLA-DR.  
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Figure 11. Reduced expression of specific miRNAs results in down-regulation of the 
DC-specific surface marker, DC-SIGN. (A) Inhibition of individual miRNAs is shown 
as the average miRNA expression level with S.E. of three different experiments 
normalised to the average levels of control transfections (neg, adjusted to 1). (B) FACS 
analyses of DCs treated with indicated miRNA inhibitors. Geometric mean fluorescence 
intensities were normalised to control transfected cells (neg, adjusted to 1) and are 
presented as relative fluorescence intensities (FI); data from five different donors are 
plotted and p-values were calculated using the Mann-Whitney test.  
 
 
Data from the DICER1 knockdown and miRNA inhibition experiments showed 
that miRNAs, particularly miR-511 and miR-99b, impact DC-SIGN expression 
and thus are likely to affect DC differentiation.  
 
 
5.2.3. Potential target genes of selected miRNAs 
To determine the importance of selected miRNAs, we searched for the targets 
of miR-511, miR-99b and miR-193b using TargetScan. We selected the top 
third of the TargetScan predicted targets (context score <-0.2) and searched the 
list for immunologically important genes present in the Immport Database 
(https://www.immport.org) (4274 genes). In addition, we compiled a second list 
of potential targets using 5 different algorithms; Targetscan 5.1 (Friedman et 
al., 2009), Miranda (John et al., 2004), DIANA-microT (Maragkakis et al., 
2009), Pictar (Krek et al., 2005) and rna22 (Miranda et al., 2006). The putative 
targets were ranked by their position in the input lists and the top 500 genes 
were used in subsequent analysis. Genes with low expression were excluded. 
The remaining lists, which contained 135–247 targets for each studied  
miRNA, were analysed using the g:GOSt tool at the g:Profiler website 
(http://biit.cs.ut.ee/gprofiler/); g:GOSt retrieves most significant Gene Ontology 
(GO) terms, together with KEGG and REACTOME pathways data (Reimand et 
al., 2007). Based in these analyses, miR-511 showed the greatest potential to 
target several pathways important in DC and macrophage differentiation, 
maturation and function (Table 5). 
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Among the Targetscan predictions, TLR4 was one of the most highly scored (3 
target sites, context score –0.89) miR-511 targets with expression in DCs. 
Therefore, we studied whether TLR4 mRNA and protein levels are influenced 
by miR-511. We followed miR-511 and TLR4 expression during the DC 
differentiation, where the miR-511 level increased during differentiation (Figure 
12A). The total amount of TLR4 mRNA was relatively constant during the 
differentiation (Figure 12B), but the protein level increased gradually to 3.4 
times compared to monocytes (Figure 12C).  
To study the impact of multiple miR-511 sites on TLR4 expression, we 
inhibited miR-511 and measured the amount of TLR4 mRNA and protein in DC 
differentiation. The TLR4 protein levels were approximately 2-fold higher in 
control cells compared with miR-511 inhibited samples (Figure 12D), cor-
relating with miR-511 accumulation in the cells (Figure 12A).  
These data showed that there is correlation between the expression of miR-
511 and an enhanced level of the TLR4 protein, suggesting that miR-511 is a 
positive regulator of TLR4 protein translation in monocyte-derived DCs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12. Expression of miR-511 correlates with an enhanced level of the TLR4 
protein in differentiating DCs. (A) The RNA expression levels of miR-511, DC-SIGN, 
and (B) TLR4 transcripts in differentiating DCs. RT-PCRs of specific genes are 
normalised to either HPRT or let-7a and the expression levels in MOs (adjusted to 1). 
(C) Western blot analysis of TLR4 in differentiating DCs and (D) in the presence of the 
miR-511 inhibitor (anti-511) or the control inhibitor (neg) are normalised to GAPDH; 
the numbers indicate the fold difference compared to the MOs (adjusted to 1, C) or to 
transfected control cells on day 2 (DC2, neg, D).  
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5.2.4. The impact of miR-511 on TLR4 
To further investigate the positive effect of miR-511 on TLR4 protein level, we 
looked whether TLR4 is directly targeted by miR-511 in LUC reporter assays. 
As TLR4 contains polyadenylation signals between each potential miR-511 
target sequence, three different fragments of TLR4 3'UTR were inserted down-
stream of the LUC coding region in the vector and were transfected alongside 
either pre-miR-511 or control pre-miRNA into the HEK293 cells. In previous 
studies, it was shown that miRNAs upregulate translation of target mRNA when 
the cell cycle is arrested (Vasudevan et al., 2007; Vasudevan et al., 2008). As 
human blood monocytes do not proliferate during differentiation and we 
observed a positive correlation between miR-511 expression and the TLR4 
protein level in differentiating DCs, we studied the cells in normal conditions 
and in contact-inhibited conditions, where cells are arrested in the G0 phase 
(Vasudevan et al., 2008). In normal growth conditions, expression of LUC 
constructs with 3'UTR fragments containing the first and second predicted 
TLR4 target sites of miR-511 (TLR4 I and TLR4 II) were downregulated in the 
presence of miR-511 (Figure 13A). LUC expression levels of TLR4 I and TLR4 
II were higher in contact-inhibited cells in the presence of transfected miR-511; 
and for the TLR4 III construct, LUC expression was significantly enhanced 
when compared to the control cells (Figure 13B).  
These data indicate that miR-511, depending on the target mRNA 3'UTR and 
the conditions, can either up- or downregulate the expression of target genes. 
 
 
Figure 13. Determining the influence of miR-511 on expression of its proposed target 
using the LUC reporter assay. (A) The LUC activity measured in normal conditions 
after 48 h and (B) in contact-inhibited conditions after 96 hours following transfection 
of the LUC reporters and either pre-miR-511 or the control pre-miRNA. LUC activity 
of the ARE reporter was used as a positive control and pGL3 as a negative control. The 
data are displayed as the means with S.E.M. of at least eight different transfections.  
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5.3. Monocyte DNA methylation profile in ageing (Ref. III) 
A diverse range of age-associated changes has been reported in human innate 
immune cells, which are important in increased susceptibility to infectious 
diseases and inflammatory pathology (Rymkiewicz et al., 2012; Solana et al., 
2012). It is therefore important to study epigenetic changes occurring in these 
cells during ageing. To describe age-related DNA methylation profiles, we 
studied monocytes from the peripheral blood of eight young (age range 22–25 
years, mean 23.75 years; 4 females and 4 males) and eight elderly healthy 
volunteers (age range 77–78 years, mean 77.13 years; 4 females and 4 males). A 
whole genome methylation analysis was performed using the Infinium 
HumanMethylation450 BeadChip (Illumina Inc.). Methylation at each CpG site 
is estimated by the Beta (β) value, ranging from 0 to 1, defined as the proportion 
of the methylated signal to the total signal and calculated from the normalised 
intensity values.  
 
Table 6. Differentially methylated sites in young versus old monocyte cell populations  
Direction of 
methylation Target ID β-difference* Adjusted p-value Gene 
Hypo- 
methylated 
cg10501210 -0.38 0.002884 miR-29b-2** 
cg24892069 -0.30 0.00312   NRP1 
cg27209729 -0.30 0.020571 NRXN2 
cg11807280 -0.27 0.013523  
cg08128734 -0.27 0.015965 RASSF5 
cg11693709 -0.26 0.024853 PAK6 
cg18826637 -0.25 0.022927  
cg00329615 -0.25 0.012874 IGSF11 
cg00740914 -0.25 0.008061  
cg03873281 -0.25 0.005647 PDLIM4 
cg13039251 -0.23 0.008793 PDZD2 
cg07583137 -0.23 0.007904 CHMP4C 
cg12317815 -0.22 0.014773 ASPA 
cg06781608 -0.22 0.030063 PTPRN2 
cg13001142 -0.22 0.011913 STXBP5 
cg16932827 -0.21 0.015062  
cg19344626 -0.21 0.010547 NWD1 
cg14295611 -0.21 0.04857  
cg14614643 -0.21 0.008462  
cg03915012 -0.21 0.026415 GAK 
cg03473532 -0.20 0.035003 MKLN1 
Hyper- 
methylated 
cg19907915  0.21 0.014934 IGSF9B 
cg20665157  0.22 0.008629 CADPS2 
cg21184711  0.23 0.024671 CADPS2 
cg04875128  0.30 0.017558 OTUD7A 
cg02978201  0.47 0.015062 PRM1 
The three replicated CpG loci are shown in bold. 
* β-difference is the difference of β-values. A negative β-difference indicates hypomethylation in 
the elderly and a positive β-difference indicates hypermethylation in the elderly. Only CpG sites 
with FDR-adjusted p-values of less than 0.05 were considered to be differentially methylated. 
**approximately 1 kb upstream 
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Altogether, we found 368 CpG sites that were significantly differentially 
methylated (p<0.05), from which 26 CpG sites had an absolute β value 
difference greater than or equal to 0.2 between the young and old individuals 
(Table 6). Most of the CpG sites, a total of 21 positions, were hypomethylated 
in the elderly individuals; only five positions were hypermethylated in these 
individuals. Decreased methylation during the ageing process has been pre-
viously described in a study of PBMCs (Johansson et al., 2013). The most 
significantly altered sites mapped within the NRP1, NRXN1, RASSF5, OTUD7A 
and PRM1 genes. The loci that did not reach the 0.2 β-difference threshold but 
were significantly different (p<0.05) included two ELOVL2 sites, cg16867657 
and cg24724428 (both with β-diff. of 0.17); two FHL2 sites, cg22454769 and 
cg24079702 (β-diff. of 0.15 and 0.14, respectively); and a PENK site, 
cg16419235 (β-diff. of 0.08); all these sites are associated with increased 
methylation in the peripheral blood mononuclear cells of older individuals 
(Garagnani et al., 2012; Johansson et al., 2013).  
To validate our results, we focused our investigation on the three diffe-
rentially methylated CpG sites with the highest hypomethylation values, 
cg24892069, cg27209729 and cg10501210. cg24892069, which had a very low 
standard deviation in both age groups (young STDEV: 0.05; old STDEV: 0.06), 
is located in the gene body of the neuropilin 1 (NRP1) gene. We replicated the 
array results of the three differentially methylated loci using the EpiTYPER 
assay (Sequenom Inc.) with a separate set of young and old samples. To our 
analyses, we added two sex-matched age groups consisting of 10 young (age 
range 24–28 years, mean 26.4 years; 5 men and 5 females) and 10 elderly (age 
range 76–84 years, mean 79.4 years; 5 men and 5 females) samples. Using the 
EpiTYPER assay, we found hypomethylation of the NRP1-associated 
cg24892069 site in the monocytes of the older individuals, similar to the results 
from the HumanMethylation450 BeadChip analysis (Figure 14A). We also 
analysed the methylation differences in men and women separately and we 
observed a significant difference in both gender groups (both p<0.0001) (Figure 
14A). To explore this region further, we selected another CpG site, 
cg24892069-40bp, which was located 40 bp upstream of the cg24892069 site in 
the genomic sequence; this site was not included on the methylation BeadChip. 
We found that the cg24892069-40bp site had a statistically significant 
methylation difference between the studied age groups (p<0.0001) that was 
observed in both sexes (p<0.0001) (Figure 14B). The similar DNA methylation 
pattern of the two CpG sites in close proximity is most likely the result of a 
shared, differentially methylated, region that is modified from the nearby 
methyltransferase binding site. We also found significant differences between 
the age groups at the cg27209729 and cg10501210 sites, located in the NRXN2 
gene and upstream of the miR-29b-2 gene, respectively (Figure 14C&D). Both 
of these CpG sites had statistically significant methylation differences in the 
combined study group (p<0.0001) and in the male and female study group 
(p<0.001 and p<0.01 in NRXN2 and p<0.0001 in miR-29b-2) (Figure 14C&D). 
45 
In summary, we demonstrated differentially methylated DNA patterns in 
monocytes of young and elderly individuals. In elderly most of the altered CpG 
sites were hypomethylated and three most hypomethylated CpG sites located in 
or near relevant genomic loci. 
 
 
Figure 14. The percentage of CpG site methylation that differs between young and 
elderly individuals (left panel) and between young and elderly men and women (right 
panel). (A) cg24892069 (NRP1), (B) cg24892069-40bp (NRP1), (C) cg27209729 
(NRXN2) and (D) cg10501210 (miR-29b-2). The mean (±S.E.M.) methylation diffe-
rence measured in young and old individuals was measured using Sequenom's 
EPITYPER assay. 
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6. DISCUSSION 
6.1. Histone modification differences in monocytes, 
monocyte-derived macrophages and dendritic cells  
(Ref. I) 
Increasing evidence shows that epigenetic modifications can influence gene 
expression profiles without affecting the DNA sequence. Recent studies have 
demonstrated that epigenetic mechanisms are involved in the inheritance of 
gene expression patterns (Sharma et al., 2010) and in mechanisms of cellular 
differentiation (Wei et al., 2009). In this study, we examined three aspects of 
the monocyte and monocyte-derived macrophage and DC system, histone mo-
difications, microRNAs and also DNA methylation changes that occur during 
ageing.  
Our genome-wide correlation of mRNA expression profiles with three major 
histone modifications was the first large scale study of gene expression 
associations with histone modifications in monocytes, macrophages and DCs; 
our derived expression profile adds to previous studies in other immune cells 
(Roh et al., 2006; Lehtonen et al., 2007; Araki et al., 2009; Wei et al., 2009; 
Ghisletti et al., 2010). The gene expression profiles of monocytes and 
monocyte-derived DCs have since been described in several other studies that 
considered different aspects that affect these cells; for example, health and 
disease, stimulation, differentiation and cell type (Robbins et al., 2008; Bull-
winkel et al., 2011; Frankenberger et al., 2012; Haniffa et al., 2012; Lundberg 
et al., 2013). Our results showed that the overall gene expression profiles of 
studied monocytes, monocyte-derived macrophages and DCs were similar but 
that there were some important differences that help to define the cell types. We 
observed greater differences between monocytes and DCs and between 
monocytes and macrophages than between DCs and macrophages. This is in 
concordance with the fact that although both DCs and macrophages have gone 
through separate differentiation processes, they have developed from the same 
cell type. 
We analysed whether observed differences in gene expression profiles 
between monocytes and monocyte-derived cells could be the consequence of 
divergent epigenetic backgrounds. First, we investigated the histone modifi-
cations in promoter regions, as it has been shown that they can regulate gene 
expression (Kouzarides, 2007). Histone marks H3K4me3 and H3K27me3 are 
usually enriched on active and inactive chromatin regions, respectively (Azuara, 
2006; Jiang et al., 2011). The most predominant histone mark in our study was 
H3K4me3, and it was commonly coupled with AcH3. H3K4me3 was also the 
most frequently found promoter modification indentified in genome-wide 
studies from embryonic stem cells, CD4+ and CD8+ T cells (Roh et al., 2006; 
Guenther et al., 2007; Zhao et al., 2007; Araki et al., 2009; Wei et al., 2009; 
Tian et al., 2011). 
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When studying the dynamics of histone modifications, we noticed a gradual 
decrease of the H3K4me3 mark in active genes during the differentiation of 
monocytes to macrophages and DCs. This suggests that a subset of genes lose 
their H3K4me3 mark during differentiation and that histone modifications may 
be highly dynamic during differentiation. Others have reported that there is a 
change towards more inactive chromatin when monocytes are differentiated into 
DCs in vitro in the presence of Toll-like receptor ligands (Huang et al., 2012). 
We found that the H3K4me3 and AcH3 marks are unstable when they occur 
alone but are stable when in combination of in gene promoters. The overall 
decrease of the H3K4me3 mark and the increase of genes with the H3K27me3 
mark in the DC population suggest that the in vitro differentiation induces a 
global shift towards less active chromatin. Therefore, monocyte differentiation 
to macrophages and DCs likely requires a different pattern of histone modi-
fications to regulate gene expression. 
In monocyte-derived DC differentiation, the role of histone modifications 
has been shown in the regulation of the DC-SIGN gene (Bullwinkel et al., 
2011). In addition, many other important immunorelated genes, including 
monocyte chemotactic protein-1 (MCP-1), TNF-α, IL-12 and IL-4, are regu-
lated by changes in histone modifications (Fields et al., 2002; Barthel and 
Goldfeld, 2003; Boekhoudt et al., 2003; Wen et al., 2008). At the single gene 
level, we found many differences in histone modification profiles that correlate 
with transcriptional changes. We detected a strong correlation between the 
H3K4me3 mark and the transcriptional activity of a gene. As expected, the 
expression levels of many marker genes correlated with the presence of active 
histone modifications. Similar to marker genes, genes associated with antigen 
presentation activity and phagocytosis had high levels of expression and had 
either the H3K4me3 or the AcH3 mark.  
 
 
6.2. miR-511 affects the differentiation of DC and 
regulates positively its putative target TLR4 (Ref. II) 
To further study differences between monocytes, monocyte-derived macro-
phages and DCs, we analysed the microRNA expression profiles of these cells. 
The importance of miRNAs in the immune system has been described in several 
different studies: miR-146 regulates the inflammatory responses in many 
different cell types through the suppression of genes in the NF-κB pathway 
(Taganov et al., 2006; De Benedetto et al., 2009; Jurkin et al., 2010); miR-155 
has a pro-inflammatory role in mouse DCs, macrophages, B and T cells 
(O'Connell and Keegan, 2006; O'Connell et al., 2007; Rodriguez et al., 2007); 
miR-34 and miR-21 function in human monocyte-derived DCs by targeting the 
mRNAs encoding Jagged1 and WNT1 (Hashimi et al., 2009); and miR-21 
functions in mouse macrophages by negatively regulating TLR4 (Sheedy et al., 
2010). In addition, several other miRNAs are involved in regulation of com-
ponents of the TLR signalling system (O'Neill et al., 2011). In our study, we 
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have described updated miRNA expression profiles of human blood monocyte-
derived immature and mature DCs and macrophages. Consistent with previous 
studies (Landgraf et al., 2007; Lehtonen et al., 2007; Ceppi et al., 2009; 
Hashimi et al., 2009; Jin et al., 2010), we found that these cell types have 
distinct miRNA expression profiles and we detected several novel strongly up-
regulated miRNAs, including miR-511.  
DC-SIGN is a marker involved in DC trafficking and T-cell contact es-
tablishment (Banchereau et al., 2000; Geijtenbeek et al., 2000), whereas CD14 
is important in monocyte function and mediates the innate immune response to 
bacterial lipopolysaccharides and thereby intracellular effects (Wright et al., 
1990). In the process of monocyte differentiation into DCs, CD14 expression is 
replaced by DC-SIGN expression and the variation of this replacement indicates 
a deviation in the differentiation process (Mirghomizadeh et al., 2009); this has 
been shown in the case of miR-99b, miR-21, miR-34a and miR-155 (Hashimi et 
al., 2009; Martinez-Nunez et al., 2009; Cekaite et al., 2010). In addition, miR-
146a is known to inhibit the maturation of monocyte-derived DC differentiation 
(Du et al., 2012). In our study, the knockdown of DICER1 with siRNAs 
resulted in lower expression of DC-SIGN and a higher level of monocyte 
marker CD14, confirming that miRNAs are needed for proper differentiation of 
DCs. Similarly, the specific inhibition of miR-511 and miR-99b resulted in a 
reduction of DC-SIGN, indicating that these two miRNAs influence DC 
differentiation. In the Illumina miRNA array analyses, only one strand of miR-
511 (miR-511-5p) was included. In a study of mouse macrophages, it was 
shown using sensistive reporter vectors that miR-511-3p is the biologically 
bioactive strand (Chang et al., 2012; Squadrito et al., 2012). As miR-511-3p 
was not present in our study, we cannot assess its differential expression in 
human cells. The miRNA strand selection mechanisms are still unclear but 
some studies have proposed that it may depend on cell type, species and the 
sequence context (Biasiolo et al., 2011; Kuchenbauer et al., 2011). 
In humans and in mice, the miR-511 gene is encoded in the mannose 
receptor gene MRC1, which is mainly expressed in DCs, macrophages and 
subsets of vascular and lymphatic endothelial cells (Taylor et al., 2005; Kerri-
gan and Brown, 2009). It is thought that miR-511 and MRC1 may be co-
ordinately regulated, and studies show that the functional activities are 
correlated (Squadrito et al., 2012). In the computational prediction of miRNA 
targets, we found that genes from ontology groups and pathways with immune 
functions are overrepresented in the list of miRNA-511 potential targets. In this 
study, we examined the possible impact of miR-511 on its proposed target 
TLR4. In contrast to the expected result, we found that knockdown of miR-511 
enhanced TLR4 protein levels in differentiating DCs. In cell cycle arrest at the 
G0 phase miRNAs can enhance the target protein level (Vasudevan et al., 2007; 
Vasudevan et al., 2008). Although human monocytes can differentiate into 
DCs, they do not proliferate and are cell cycle arrested. The alternative possi-
bility is that miR-511 competes with degradation factor, as has been shown for 
miR-466, which replaces tristetraprolin (TTP) protein and therefore upregulates 
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the mRNA and protein level of IL-10 (Ma et al., 2010). In some cases, the 
mechanism of expression enhancement is not clear, such as for miR-155, which 
has a stabilising influence on TNF-α mRNA in macrophages (Tili et al., 2009; 
Bala et al., 2011). The influence of miR-511 on TLR4 protein expression seems 
to be direct, as the presence of miR-511 in HEK293 cells reduced Luciferase 
levels for TLR4-I and TLR4-II in normal conditions and enhanced the LUC 
level for TLR4-III in contact inhibited cells.  
 
 
6.3. Distinct age-related methylation patterns  
in human monocytes (Ref. III) 
We also studied changes in DNA methylation that occur in monocyte cells 
during ageing as ageing affects many components of the immune system, in-
cluding the innate and adaptive immune responses. A diverse range of age-
associated changes has been reported in human innate immune cells, which are 
important during the early response to pathogens. Although the number of 
monocytes does not change significantly during ageing, several functional age-
related changes have been reported, such as the altered expression of cytokines, 
defective Toll-like receptor signalling and a decreased capacity for phago-
cytosis. Changes in DNA methylation patterns occur gradually throughout an 
individual's lifespan (Bell et al., 2012; Garagnani et al., 2012) and may result in 
the age-related phenotypes of a specific set of genes (Bell et al., 2012). Corre-
lation between gene expression and methylation has been shown in studies of 
lymphoblastoid cell lines and monocytes that incorporated 77 and 1264 sub-
jects, respectively (Bell et al., 2011; Liu et al., 2013). The same methylation 
patterns evident in ageing also appear in cancer development (Esteller, 2008).  
In our study of DNA methylation in ageing, we found 368 CpG sites that 
were significantly differentially methylated, of which 26 CpG sites had absolute 
β value differences greater than or equal to 0.2 in the young and old individuals; 
most of the CpG sites were hypomethylated in the elderly individuals. De-
creased methylation during the ageing process has been previously described in 
a study of PBMCs (Johansson et al., 2013). However, PBMCs are a mixture of 
different cell types, and the observed changes in DNA methylation may result 
from age-related changes in cell composition. It has been shown that DNA 
methylation depends on the cell composition (Reinius et al., 2012; Liu et al., 
2013). From the 26 CpG sites, the most significantly changed loci mapped 
within the NRP1, NRXN1, RASSF5, OTUD7A and PRM1 genes. The signifi-
cantly different loci included sites are associated with increased methylation in 
peripheral blood mononuclear cells from older individuals; ELOVL2 sites 
cg16867657 and cg2472442; FHL2 sites cg22454769 and cg24079702 and 
PENK site cg16419235 (Garagnani et al., 2012; Johansson et al., 2013). We 
validated our results on the three differentially methylated CpG sites with the 
highest hypomethylation values, cg24892069, cg27209729 and cg10501210. 
These three sites are located in or near immunologically important genes, 
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cg24892069b in the NRP1 gene body, cg27209729 in the NRXN2 gene body, 
and cg10501210 ~1000 bp upstream of the miR-29b-2 gene. NRP1 is a cell 
surface receptor with functional roles in several biological processes, including 
angiogenesis, immune response, the regulation of vascular permeability, 
development of the nervous system (Miao et al., 2000; Geretti et al., 2007). 
NRP1 has also been associated with increased tumour angiogenesis and cancer 
progression (Bielenberg et al., 2006; Bagri et al., 2009). In our previous mRNA 
expression study, NRP1 was expressed at low levels in monocytes and 
demonstrated a significantly increased expression in monocyte-derived DCs and 
macrophages (Paragraph 0). NRP1 is also expressed in regulatory T cells 
(Bruder et al., 2004) and is needed for prolonged cellular contact between 
regulatory T-cells and DCs (Sarris et al., 2008). Another CpG site, cg27209729, 
is located in the body of the neurexin 2 (NRXN2) gene. NRXN2 is a member of 
the neurexin family, which affects synaptic plasticity and cognitive functioning 
(Rozic et al., 2012), and has been linked to autism spectrum disorders and 
schizophrenia (Gauthier et al., 2011). The third CpG site, cg10501210, is 
located ~1,000 bp upstream of the miR-29b-2 gene. miR-29b-2 belongs to the 
miR-29 family, which is important in thymic involution (Papadopoulou et al., 
2012), T cell polarisation (Ma et al., 2011) and oncogenesis (Santanam et al., 
2010; Papadopoulou et al., 2012).  
DNA methylation in gene promoters is usually associated with transcrip-
tional silencing (Thomson et al., 2010), while methylation in the gene body is 
associated with transcriptional activation (Portela and Esteller, 2010). Many 
studies have shown that men a have higher global DNA methylation level than 
women (El-Maarri et al., 2007; Zhu et al., 2010; El-Maarri et al., 2011; Zhang 
et al., 2011), but we could not detect this difference in our study of CpG sites. 
Global DNA methylation can also be influenced by demographic, environ-
mental and behavioural risk factors; for example, ethnicity (Axume et al., 2007; 
Terry et al., 2008), air pollution (Baccarelli et al., 2009; Tarantini et al., 2009), 
smoking (Philibert et al., 2009; Breitling et al., 2011), alcohol (Bonsch et al., 
2004; Bleich et al., 2006; Hamid et al., 2009) and dietary preferences (Kok et 
al., 2007; Heijmans et al., 2008). Despite these reports, there are large scale 
studies showing that basic epigenetic features are common across sex and 
ethnicities (Liu et al., 2013), suggesting that sample size and composition can 
significantly affect reported correlations. 
 
 
6.4. Closing remarks 
In this thesis, we provide a large-scale epigenetic characterisation of changes 
that occur in the differentiation of monocyte-derived macrophages and DCs. We 
described distinct gene expression, histone modification and microRNA profiles 
in monocytes, monocyte-derived macrophages and DCs. Gene expression pro-
files correlated with histone modification patterns. A novel macrophage and DC 
specific miRNA, miR-511, which has strong immunoregulatory potential, was 
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described. In addition, we found several differentially methylated CpG sites in 
the monocytes of elderly individuals.  
Our findings form a good basis for further epigenetic studies in monocytes 
and monocyte-derived cells and aid in the understanding of the novel mecha-
nisms of gene regulation that have roles in differentiation. Our results may be 
useful to better understand the role of epigenetics in ageing and to provide new 
approaches to control inflammatory processes.  
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7. CONCLUSIONS 
1. Monocytes, macrophages and dendritic cells have different gene expression 
and histone modification patterns. In the studied cells, the most prevalent 
histone mark is H3K4me3, but there were changes in the overall histone 
mark pattrens during the differentiation process. Histone marks can be 
correlated with gene transcriptional activity and functional properties. 
2. We have determined updated miRNA expression profiles for human blood 
monocytes, macrophages and dendritic cells and have found miR-511 to be 
a highly expressed macrophage and dendritic cell specific miRNA with 
strong immunoregulatory potential. In addition, our data highlight that the 
cellular environment can modulate the influence of miRNAs. 
3. Purified monocytes from young and elderly individuals have differentially 
methylated DNA patterns; most of the altered CpG sites were hypo-
methylated in the elderly. We determined the three most frequently hypo-
methylated CpG sites located in or near relevant genomic loci. 
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SUMMARY IN ESTONIAN 
Monotsüütide, monotsüütidest pärinevate makrofaagide ja 
dendriitrakkude epigeneetilised profiilid 
Inimese immuunsüsteem koosneb kaasasündinud ning omandatud immuun-
susest, millest esimene tagab kiire, kuid mitte nii spetsiifilise reaktsiooni pato-
geenide vastu, ning teine väga spetsiifilise immuunvastuse ning immunoloo-
gilise mälu. Sillana kahe erineva immuunsüsteemi osa vahel toimivad dendriit-
rakud, mis on peamised antigeeni esitlevad rakud immuunsüsteemis. Dendriit-
rakud tunnevad patogeenid ära spetsiifiliste ohuretseptorite abil, esitavad anti-
geene T rakkudele ja seeläbi vallandavad omandatud immuunvastuse ning 
vahendavad erinevate immuunrakkude ja antikehade abil organismi puhastamist 
patogeenidest. Koostöös monotsüütide, makrofaagide ning teiste immuun-
rakkudega tagavad dendriitrakud organismi homöostaasi.  
Normaalsetes tingimustes ei läbi dendriitrakud ja makrofaagid diferentsee-
rumisel monotsüüdi etappi, kuid põletikulistes tingimustes toimub dendriit-
rakkude ja makrofaagide arvu kiire kasv just monotsüütide kaudu, mis värva-
takse kiiresti põletikukoldesse. Dendriitrakkude uurimist raskendab asjaolu, et 
nende kontsentratsioon inimese perifeerses veres on väga madal (< 1 % mono-
nukleaarsetest rakkudest). In vitro tingimustes saab dendriitrakke ja makrofaage 
diferentseerida monotsüütidest, kasutades granulotsüüdi makrofaagi kolooniat 
stimuleerivat faktorit (granulocyte macrophage colony-stimulating factor - GM-
CSF) ja interleukiin 4 (IL-4). Selliseid rakke kasutatakse laialdaselt erinevates 
uuringutes, kuna neid on suhteliselt lihtne suurtes hulkades toota.  
Epigeneetika on teadus, mis üritab selgitada, kuidas piiratud arv geene suu-
dab määratleda diferentseerumist erinevateks rakutüüpideks ning kuidas feno-
tüüp pärandatakse ühelt tütarrakult teisele, sealjuures ilma DNA järjestust muut-
mata. Epigeneetiliste modifikatsioonide tähtsus geeniekspressiooni regulat-
sioonis on viimasel ajal väga palju tähelepanu pälvinud valdkond. Epigenee-
tiliste modifikatsioonide rolli tähtsust on näidatud mitmete erinevate protses-
sides, nagu rakutsükli regulatsioon, organismi areng ja vananemine ning X 
kromosoomi inkativatsioon. Käesolev uurimistöö uurib monotsüüte ning mono-
tsüütidest diferentseeritud makrofaage ja dendriitrakke kolmest erinevast aspek-
tist: histooni modifikatsioonide seos geeniekspressiooniga, mikroRNAde 
(miRNAd) ekspressiooni mõju nimetatud rakkudes ning DNA metülatsiooni 
monotsüütides vananemisel. 
Käesolev ülegenoomi töö on oluline lisa eelnevalt avaldatud mRNA ja 
miRNA ekspressiooni ja histooni modifikatsioone käsitletavatele uuringutele 
immuunsüsteemi rakkudes. Uurimaks ekspressioonimustrite ja epigeneetiliste 
modifikatsioonide vahelisi seoseid, analüüsisime geenide promootorite regioo-
nides kolme kõige levinumat histooni modifikatsiooni, millest H3K4m3 ja 
AcH3 tähistavad aktiivset ja H3K27me3 inaktiivset geeni. Kõige levinum 
uuritud modifikatsioonidest oli aktiivne märgis H3K4me3, mis tihtipeale esines 
koos märgisega AcH3. Täheldasime, et histooni modifikatsioonid üksinda ei ole 
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väga stabiilsed ning kaotavad olemasoleva või omandavad uue modifikatsiooni 
makrofaagide ja dendriitrakkude diferentseerumise käigus. Uurides eraldi 
aktiivseid ja inaktiivseid geene, nägime suurepärast korrelatsiooni geeni aktii-
vuse ja histooni märgiste vahel, kus inaktiivsed geenid olid tähistatud pigem 
märgisega H3K27me3 ning aktiivsed geenid märgistega H3K4me3 ja AcH3. 
Kuna fagotsütoos ja antigeeni esitlemine on monotsüütide ja monotsüütidest 
diferentseeritud rakkude peamised funktsioonid, siis uurisime ka geene, mis on 
seotud nende võtmefunktioonidega. Ka siin nägime väga head korrelatsiooni 
nimetatud funktsioonide, geeni aktiivuse ja histooni modifikatsioonide vahel.  
miRNAd on väikesed mittekodeerivad RNA molekulid, mis reguleerivad 
märklaudgeeni ekspressiooni taset rakus. miRNAde rolli olulisust on näidatud 
mitmetes erinevates bioloogilistes protsessides, sealhulgas ka immuunsüsteemi 
funktsioneerimisel. Kooskõlas eelnevate uuringutega kirjeldasime nii eba-
küpsete kui ka küpsete dendriitrakkude ja makrofaagide miRNA ekspressiooni 
profiilid ning leidsime mitmeid uusi ülesreguleeritud miRNAsid, sealhulgas 
varem kirjeldamata miR-511. Kasutades miRNA protsessinguks vajaliku faktori 
DICER1 ja spetsiifiliste miRNAde vaigistamist, näitasime, et miRNA-511 ning 
ka miR-99b mõjutavad dendriitrakkude diferentseerumist. miR-511 potent-
siaalsete märklaudade hulka kuuluvad mitmed immunoloogiliste funktsiooni-
dega geenid. Uurisime ühte parima skooriga miR-511 võimaliku märklaua 
TLR4 mRNA ekspressiooni ja valgu taset ning leidsime, et mittejagunevates 
dendriitrakkudes miR-511 inhibitsiooni tulemusena tema märklaudgeeni TLR4 
ekspressiooni tase suureneb.  
Edasi vaatasime monotsüütide rakupopulatsioonis DNA metülatsiooni noor-
tel ja vanadel indiviididel. Monotsüütide arv vananemise käigus küll oluliselt ei 
muutu, kuid erinevusi on täheldatud nende funktsioonides. DNA metülatsiooni 
muutused toimuvad järk-järgult kogu inimese eluea jooksul ning aitavad kaasa 
teatud geenide vanusest sõltuva fenotüübi tekkele. Leidsime oma uuringus 368 
CpG saiti, mis olid statistiliselt erinevalt metüleeritud, kusjuures 26 CpG saiti 
olid sellised, mille β väärtuse erinevus oli suurem või võrdne 0,2-ga noorte ja 
vanade populatsiooni vahel. Kooskõlas eelnevalt avaldatud DNA metülatsiooni 
uuringuga perifeerse vere mononukleaarsetes rakkudes, nägime enamusel 
vanusegruppide vahel olulisi erinevusi antud aladel hüpometülatsiooni vanades 
indiviidides. Kõige enam hüpometüleeritud CpG aladel teostasime ka tulemuste 
valideerimise, kus nägime suuremat metülatsiooni erinevust nii naiste kui 
meeste populatsioonis. 
Kokkuvõtteks tõestavad saadud tulemused, et monotsüütide diferentseeri-
misel makrofaagideks ja dendriitrakkudeks leiavad aset mitmed epigeneetilised 
muutused. Kirjeldasime uuritud rakkude erinevat geeniekspressiooni, histooni 
modifikatsioone ning miRNA profiilid. Nägime suurepärast korrelatsiooni 
geeniekspressiooni ning histooni modifikatsioonide vahel ning kirjeldasime uue 
dendriitraku ja makrofaagi spetsiifilise miRNA, miR-511. Samuti leidsime 
mitmeid erinevalt metüleeritud CpG alasid noortes ja vanades indiviidides. 
Kokkuvõttes on käesolev töö erinevate epigeneetiliste muutuste põhjalik kirjel-
dus, mille alusel on võimalik avastada uusi geeniregulatsiooni mehhanisme ning 
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nende osa makrofaagide ja dendriitrakkude diferentseerumises. Lisaks näitavad 
meie tulemused, et vananemisel leiavad aset epigeneetilised muutused mono-
tsüütides, mis võivad aidata kaasa uute  põletikulisi protsesse kontrollivate ravi-
meetodite väljatöötamisel tulevikus.  
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